Page last updated: 2024-12-05

phenylethyl alcohol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenylethyl Alcohol: An antimicrobial, antiseptic, and disinfectant that is used also as an aromatic essence and preservative in pharmaceutics and perfumery. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-phenylethanol : A primary alcohol that is ethanol substituted by a phenyl group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6054
CHEMBL ID448500
CHEBI ID49000
SCHEMBL ID1838
MeSH IDM0016505

Synonyms (181)

Synonym
smr000059156
MLS001066349
AC-18484
EN300-19347
benzylmethanol
2-hydroxyethylbenzene
phenyl ethyl alcohol
fema no. 2858
phenethyl alcohol (natural)
epa pesticide chemical code 001503
nsc 406252
beta-fenylethanol [czech]
beta-phenylethanol
benzylcarbinol
hsdb 5002
fema number 2858
brn 1905732
beta-fenethylalkohol [czech]
1-phenyl-2-ethanol
caswell no. 655c
einecs 200-456-2
ai3-00744
D00192
phenylethyl alcohol (usp)
beta-phenethyl alcohol
beta-hydroxyethylbenzene
benzeneethanol
inchi=1/c8h10o/c9-7-6-8-4-2-1-3-5-8/h1-5,9h,6-7h
2-phenyl-ethanol
.beta.-phenylethyl alcohol
.beta.-pea
nsc406252
nsc-406252
wln: q2r
.beta.-hydroxyethylbenzene
.beta.-phenethyl alcohol
phenylethanol
2-pea
methanol, benzyl-
phenethanol
2-phenethyl alcohol
benzyl carbinol
2-phenylethyl alcohol
phenylethyl, b- alcohol
ethanol, 2-phenyl-
.beta.-phenylethanol
PEL ,
CHEBI:49000 ,
C05853
2-phenylethanol
60-12-8
phenethyl alcohol
phenylethyl alcohol
HY1 ,
phenethyl alcohol, natural, >=99%, fcc, fg
phenethyl alcohol, >=99%, fcc, fg
DB02192
NCGC00166215-01
2-phenylethanol, >=99.0% (gc)
MLS001336026
phenethylalcohol
0DE4CADC-AB8A-4038-BD6F-EBD009885652
HMS2093H05
AKOS000249688
beta-phenylethyl alcohol
beta-pea
BMSE000659
P0084
CHEMBL448500
.beta.-(hydroxyethyl)benzene
A832606
NCGC00166215-02
NCGC00166215-03
carbinol, benzyl
beta phenylethanol
alcohol, phenylethyl
alcohol, phenethyl
2 phenylethanol
4-06-00-03067 (beilstein handbook reference)
unii-ml9lga7468
beta-fenylethanol
beta-fenethylalkohol
ec 200-456-2
phenylethyl alcohol [usp]
ml9lga7468 ,
2-phenylethan-1-ol
tox21_303383
cas-60-12-8
NCGC00257347-01
dtxsid9026342 ,
dtxcid206342
tox21_113544
tox21_201322
NCGC00258874-01
nsc759116
nsc-759116
pharmakon1600-01505398
phenyl ethanol(natural)
1321-27-3
ethanol, phenyl-
bdbm85807
nsc_6054
cas_60-12-8
HMS2233H06
S3703
benzenethanol
STL281950
FT-0673679
FT-0613332
phenylethyl alcohol [usp-rs]
phenethyl alcohol [who-dd]
phenylethyl alcohol [hsdb]
phenethyl alcohol [inci]
phenylethyl alcohol [ii]
(2-hydroxyethyl)benzene
phenylethyl alcohol [usp monograph]
phenethyl alcohol [mi]
phenylethyl alcohol [fhfi]
phenethyl alcohol [fcc]
phenethyl alcohol [mart.]
HMS3374P04
CCG-213419
a-pea
SCHEMBL1838
NCGC00166215-05
tox21_113544_1
betaphenylethyl alcohol
2-phenyl ethanol
2-(2-hydroxyethyl)benzene
benzene-ethanol
2-phenyl-1-ethanol
Q-200318
phenylethyl, beta- alcohol
2-phenethanol
hydroxyethylbenzene
.beta.-p.e.a.
.beta.-fenethylalkohol
.beta.-phenethanol
mellol
.beta.-fenylethanol
AB00698274_05
mfcd00002886
F0001-1575
sr-01000763553
SR-01000763553-2
phenylethyl alcohol, united states pharmacopeia (usp) reference standard
phenylethyl alcohol (ii)
methanol, benzyl
phenethyl alcohol (mart.)
(beta-pea)
beta-(hydroxyethyl)benzene
2-phenylethane-1-ol
phenylethyl alcohol (usp monograph)
phenylethyl alcohol (usp-rs)
fema number 2858.
phenylethyl alcohol, pharmaceutical secondary standard; certified reference material
2-phenylethanol, 99%
2-phenylethanol, usp
phenyl-ethanol
phenylethyl alcohol, usan
phenethyl alcohol, 8ci, ban
benzeneethanol, 9ci
fema 2858
beta -hydroxyethylbenzene
b-hydroxyethylbenzene
benzyl ethyl alcohol
benzyl-methanol
2-phenyiethanol
SBI-0206858.P001
CS-B1821
HY-B1290
Q209463
BBL036905
phenylethyl alcohol;phenethyl alcohol;benzeneethanol
BCP32115
phenylethyl-alcohol
D70868
19601-20-8
2-phenylethanol;2-phenylethyl alcohol;benzeneethanol;phenylethanol
phenethylalcohol-d5
Z104473586

Research Excerpts

Overview

Phenylethyl alcohol is a member of the fragrance structural group Aryl Alkyl Alcohols. It is a primary alcohol.

ExcerptReferenceRelevance
"Phenylethyl alcohol is a member of the fragrance structural group Aryl Alkyl Alcohols and is a primary alcohol."( Fragrance material review on phenylethyl alcohol.
Api, AM; Jones, L; Letizia, CS; Scognamiglio, J, 2012
)
1.39

Toxicity

ExcerptReferenceRelevance
"The active component of the honeybee hive product propolis, caffeic acid phenethyl ester (CAPE), induces a selective growth suppressive and toxic effect toward cloned rat embryo fibroblast cells transformed by adenovirus type 5 (Ad5) or the Ad5 E1A transforming gene versus untransformed cloned rat embryo fibroblast cells (Z-z."( Growth suppression and toxicity induced by caffeic acid phenethyl ester (CAPE) in type 5 adenovirus-transformed rat embryo cells correlate directly with transformation progression.
Fisher, PB; Grunberger, D; Lin, J; Su, ZZ, 1994
)
0.29
"3,4-Dihydroxyphenylacetaldehyde (DOPAL) is a toxic metabolite formed by the oxidative deamination of dopamine."( 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Eisenhofer, G; Harvey-White, J; Kirk, K; Kopin, IJ; Lamensdorf, I; Nechustan, A, 2000
)
0.31
" Our results indicated that CAPE acts in the kidney as a potent scavenger of free radicals to prevent the toxic effects of GEN both at the biochemical and histological level."( Protective role of caffeic acid phenethyl ester (cape) on gentamicin-induced acute renal toxicity in rats.
Acet, A; Bay-Karabulut, A; Parlakpinar, H; Polat, A; Tasdemir, S; Ucar, M; Vardi, N, 2005
)
0.33
" These findings confirm a key role for glutathione in protecting cells from CsA-induced adverse effects and do not support a direct link between CsA-mediated ROS generation and adverse renal effects."( Diverse effects of natural antioxidants on cyclosporin cytotoxicity in rat renal tubular cells.
Capasso, G; Chiodini, P; Della Ragione, F; Di Gennaro, CI; Galletti, P; Indaco, S; Manna, C; Migliardi, V; Zappia, V, 2005
)
0.33
" The protective effects of the tested extracts or isolated compounds were evaluated from their ability to decrease hydrogen peroxide-induced formation of single strand breaks in the nuclear DNA, while the toxic effects were estimated from the increase of DNA damage when the extracts or isolated compounds were incubated directly with the cells."( DNA protecting and genotoxic effects of olive oil related components in cells exposed to hydrogen peroxide.
Agalias, A; Aligiannis, N; Bazios, D; Doulias, PT; Galaris, D; Mitakou, S; Nousis, L, 2005
)
0.33
" Caffeic acid phenethyl ester (CAPE), a component of honeybee propolis, protects tissues from reactive oxygene species mediated oxidative stress in ischemia-reperfusion and toxic injuries."( Lithium-induced renal toxicity in rats: protection by a novel antioxidant caffeic acid phenethyl ester.
Akturk, O; Altuntas, I; Oktem, F; Olgar, S; Ozguner, F; Sulak, O; Yilmaz, HR, 2005
)
0.33
" Adverse effects of TAM include hepatotoxicity."( Caffeic acid phenethyl ester protects against tamoxifen-induced hepatotoxicity in rats.
Abdel-Naim, AB; Albukhari, AA; El-Beshbishy, HA; Gashlan, HM; Nagy, AA, 2009
)
0.35
" However, its widespread use is restricted because it has serious toxic effects on the kidney."( Protective effect of caffeic acid phenethyl ester on cyclosporine A-induced nephrotoxicity in rats.
Aydin, M; Davarci, M; Gökçe, A; Ilhan, S; Oktar, S; Ozkan, OV; Yalçinkaya, FR; Yönden, Z, 2009
)
0.35
"Arsenic trioxide (ATO) treatment is a useful therapy against human acute promyelocytic leukemia (APL), however, it concomitantly brings potential adverse consequences including serious side effect, human carcinogenicity and possible development of resistance."( Cytotoxicity of arsenic trioxide is enhanced by (-)-epigallocatechin-3-gallate via suppression of ferritin in cancer cells.
Cheng, IC; Lee, TC; Shue, JJ; Wang, TC, 2011
)
0.37
" L-Buthionine-SR-sulfoximine treatment exerted an additive toxic effect on the CP-treated animals."( In vivo prevention of bladder urotoxicity: purified hydroxytyrosol ameliorates urotoxic effects of cyclophosphamide and buthionine sulfoximine in mice.
Cherif, M; Elgaaied, AB; Hamden, K; Hamrita, B; Jaouadi, B; Kouidi, S; Medimegh, I; Messai, Y; Ouerhani, S; Rouissi, K, 2011
)
0.37
"Humans are exposed to dietary acrylamide (AA) during their lifetime, it is therefore necessary to investigate the mechanisms associated with AA-induced toxic effects."( Olive oil hydroxytyrosol reduces toxicity evoked by acrylamide in human Caco-2 cells by preventing oxidative stress.
Bravo, L; Goya, L; Martín, MÁ; Ramos, S; Rodríguez-Ramiro, I, 2011
)
0.37
"3 mg/kg per day from the use of multiple consumer personal care products containing PEA, a rat dermal no observed adverse effect level of 70 mg/kg per day, and the percentage of dose absorbed in humans, the margin of safety exceeds 2600 concluding that, under normal fragrance use conditions, PEA is not a developmental toxicity hazard for humans."( The pharmacokinetics of phenylethyl alcohol (PEA): safety evaluation comparisons in rats, rabbits, and humans.
Api, AM; Christian, MS; Diener, RM; Hawkins, DR; Politano, VT; Ritacco, G,
)
0.44
" There are some studies suggesting oxidative stress-induced toxic changes on liver related to AFB1 toxicity."( Caffeic acid phenethyl ester modulates aflatoxin B1-induced hepatotoxicity in rats.
Akçam, M; Artan, R; Gelen, T; Nazıroğlu, M; Ozdem, S; Yilmaz, A, 2013
)
0.39
"Paraquat (PQ), which is used extensively as a potent herbicide throughout the world, is highly toxic in humans."( Protective effects of caffeic acid phenethyl ester on the dose-dependent acute nephrotoxicity with paraquat in a rat model.
Davarci, M; Dorum, BA; Gokce, H; Nacar, A; Rifaioglu, MM; Sefil, F, 2015
)
0.42
" Safety measures included discontinuation rate, treatment-emergent adverse events, serious adverse events, and vital signs."( Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.
Atkinson, S; Ball, SG; Bangs, M; Dubé, S; Goldberger, C; Sparks, J, 2015
)
0.42
" The lowest observed adverse effect level (LOAEL) was the 500 mg HT/kg bw/day based on statistically significant reductions in body weight gain and decreased body weight in males."( Toxicological evaluation of an olive extract, H35: Subchronic toxicity in the rat.
Anyangwe, N; Beilstein, P; Edwards, J; Heilman, J; López, J; Tran, N, 2015
)
0.42
" HC-HT CSNPs exhibited LD50 > 125 mg/body surface area of active, which is 100-fold higher than the normal human dose of HC."( Minimization of Local and Systemic Adverse Effects of Topical Glucocorticoids by Nanoencapsulation: In Vivo Safety of Hydrocortisone-Hydroxytyrosol Loaded Chitosan Nanoparticles.
Amin, MCIM; Buang, F; Jamil, A; Katas, H; Ng, SF; Siddique, MI; Zulfakar, MH, 2015
)
0.42
"In the ethanol group, TAS levels were significantly lower than the other groups and this finding indicates that the toxic effect of ethanol reduces antioxidant levels."( Protective Effects of Intralipid and Caffeic Acid Phenyl Esther (CAPE) on Neurotoxicity Induced by Ethanol in Rats.
Basarslan, SK; Kaplan, I; Korkmaz, M; Osun, A; Ozkan, U; Senol, S, 2017
)
0.46
" The safety assessments included the incidence of adverse events, vital signs, electrocardiograms, laboratory tests, percentile changes in weight, height, and body mass index, and Tanner staging."( Long-Term, Open-Label, Safety Study of Edivoxetine Monotherapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Ahl, J; Bangs, M; Liu, P; Nery, ESM; Perahia, D, 2017
)
0.46
"9%; N = 264) experienced at least one adverse event."( Long-Term, Open-Label, Safety Study of Edivoxetine Monotherapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Ahl, J; Bangs, M; Liu, P; Nery, ESM; Perahia, D, 2017
)
0.46
"Hydrocortisone (HC), topical glucocorticoid along with hydroxytyrosol (HT), and anti-microbial- and anti-oxidant-loaded chitosan nanoparticles (CSNPs) were prepared in large scale and analyzed for their adverse effects on healthy human skin followed by repeated applications."( Potential treatment of atopic dermatitis: tolerability and safety of cream containing nanoparticles loaded with hydrocortisone and hydroxytyrosol in human subjects.
Jamil, A; Katas, H; Mohd Amin, MCI; Nadeem, SM; Ng, SF; Siddique, MI; Zulfakar, MH, 2019
)
0.51
"Cisplatin is a highly effective chemotherapeutic drug that is toxic to the peripheral nervous system."( Caffeic Acid Phenethyl Ester (CAPE) Protects PC12 Cells from Cisplatin-Induced Neurotoxicity by Activating the NGF-Signaling Pathway.
Dos Santos, AC; Dos Santos, NAG; Fernandes, LS; Ferreira, RS; Martins, NM, 2018
)
0.48
" Phosphatidyl-hydroxytyrosol administered in a single oral gavage dose of 2000 mg/kg of body weight (bw) resulted in no adverse events or mortality."( Acute and repeated dose (28 days) oral safety studies of phosphatidyl-hydroxytyrosol.
Anadón, A; Ares, I; Casado, V; Martin, D; Martínez, MA; Martínez-Larrañaga, MR; Reglero, G; Torres, C; Vazquez, L, 2018
)
0.48
"Toluene is an organic solvent that is toxic to humans."( Protective effects of caffeic acid phenethyl ester and thymoquinone on toluene induced liver toxicity.
Akbas Tosunoglu, E; Bayındır, N; Bulut, H; Esrefoglu, M; Kurbetli, N; Meral, I; Meydan, S; Ozturk, O; Selek, S, 2019
)
0.51
"Peripheral sensory neuropathy (PSN) is a well-known side effect of cisplatin characterized by axonal damage."( Caffeic Acid Phenethyl Ester (CAPE) Protects PC12 Cells Against Cisplatin-Induced Neurotoxicity by Activating the AMPK/SIRT1, MAPK/Erk, and PI3k/Akt Signaling Pathways.
Amaral, L; Bernardes, CP; Dos Santos, AC; Dos Santos, NAG; Ferreira, RS; Fontana, ACK; Sisti, FM, 2019
)
0.51
"The HT-based product is effective and safe in preventing recurrent candida episodes and improves the quality of life and sexual function of treated women."( Efficacy and safety of oral administration of a product based on hydroxytyrosol as preventive therapy for recurrent vulvo-vaginal candidosis: a prospective observational pilot study.
Di Pinto, A; Luffarelli, P; Oliva, C; Prata, G; Schiavi, MC; Scudo, M; Zullo, MA, 2020
)
0.56
" Taken together, data from this work reveal that HT itself possesses toxic effect on HCs mainly thorough AIF-dependent apoptosis, while, it aggravates the ototoxicity-caused by cisplatin via both JNK and AIF pathways related apoptosis."( Hydroxytyrosol enhances cisplatin-induced ototoxicity: Possible relation to the alteration in the activity of JNK and AIF pathways.
Li, J; Man, R; Yang, H; Yang, Q; Yu, X; Zhang, W, 2020
)
0.56
" Although this effect occurs with the formation of differently toxic products, the molecular basis of this inhibition is still unclear."( Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
Acquasaliente, L; Bucciantini, M; Fongaro, B; Leri, M; Palazzi, L; Polverino de Laureto, P; Stefani, M, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic analysis indicates a fast and extensive uptake of the molecule by the organs and tissues investigated, with a preferential renal uptake."( Pharmacokinetics and metabolism of hydroxytyrosol, a natural antioxidant from olive oil.
Capasso, G; D'Angelo, S; Galletti, P; Manna, C; Mazzoni, O; Migliardi, V; Morrica, P; Pontoni, G; Zappia, V, 2001
)
0.31
"The main pharmacokinetic parameters ofp-tyrosol upon intravenous injection have been experimentally studied in rats."( [The main pharmacokinetic parameters of p-tyrosol upon intravenous injection in rats].
Cherkashina, IV; Chernysheva, GA; Krysin, AP; Plotnikov, MB; Smol'niakova, VI; Sorokina, IV; Tolstikova, TG,
)
0.13
"The main pharmacokinetic parameters of p-tyrosol after single (in 3 doses) and repeated intravenous injection were studied in rats."( [The main pharmacokinetic parameters of p-tyrosol upon intravenous injection in rats. II. Verification of the pharmacokinetics linearity and evaluation of the possible accumulation].
Cherkashina, IV; Chernysheva, GA; Krysin, AP; Plotnikov, MB; Smol'iakova, VI; Sorokina, IV; Tolstikova, TG,
)
0.13
"The pharmacokinetic profiles of caffeic acid phenethyl ester (CAPE) and its catechol-ring fluorinated derivative (FCAPE) were determined in rats after intravenous administration of 5, 10 or 20 mg/kg for CAPE and 20 mg/kg for FCAPE, respectively."( Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats.
Bowman, PD; Kerwin, SM; Maffucci, JA; Newman, RA; Pade, DS; Pang, J; Stavchansky, S; Wang, X, 2009
)
0.35
" In order to have a good understanding of its pharmacokinetic characters, the paper describes the dose-dependent pharmacokinetics of TG in rats after oral and intravenous administration."( Dose-dependent pharmacokinetics of tyrosol galactoside as an anti-fatigue drug in rats.
Deng, Y; Ding, Z; Liu, X; Wang, Q; Wang, Y, 2011
)
0.37
" The time to maximum concentration (t(max)) of edivoxetine was ∼2 hours, which was followed by a mono-exponential decline in plasma concentrations with a terminal elimination half-life (t(1/2)) of ∼6 hours."( Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder.
Allen, AJ; Dean, RA; Jin, L; Kielbasa, W; Lachno, DR; Quinlan, T; Xu, W, 2012
)
0.38
" This study investigated its in vivo anticancer efficacy and its pharmacokinetic and metabolic characteristics."( Antitumor activity of caffeic acid 3,4-dihydroxyphenethyl ester and its pharmacokinetic and metabolic properties.
Guo, X; He, Q; Lian, XY; Shen, L; Tong, Y; Wu, G; Ye, X; Yu, S; Zhang, J; Zhang, Z; Zou, L, 2013
)
0.39
" Overall, the GLSM of the ratio [impaired : normal] of Cmax was slightly less than or approximately 1 across the hepatic and renal impairment groups."( The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.
Kielbasa, W; Luffer-Atlas, D; Mitchell, MI; Tesfaye, E; Turik, MA, 2013
)
0.39
" This method was used to determine the pharmacokinetic profiles of CAPA and CAPE in male Sprague-Dawley rats following intravenous bolus administration of 5, 10 and 20 mg/kg of CAPA and 20 mg/kg of CAPE."( Development and validation of an LCMS method to determine the pharmacokinetic profiles of caffeic acid phenethyl amide and caffeic acid phenethyl ester in male Sprague-Dawley rats.
Bowman, PD; Kerwin, SM; Stavchansky, S; Yang, J, 2014
)
0.4
" The tmax is ∼ 2 h post-dose, and the plasma t1/2 is ∼ 4 - 6 h irrespective of the dose."( A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder.
Brinda, BJ; Markowitz, JS, 2014
)
0.4
" The pharmacokinetic and pharmacodynamic profile of these drugs in plasma and cerebrospinal fluid (CSF) was assessed."( A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition.
Kielbasa, W; Pan, A; Pereira, A, 2015
)
0.42
" Pharmacokinetic and pharmacodynamic data were obtained from healthy subjects (n = 160) from 5 clinical trials."( Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans.
Kielbasa, W; Lobo, E, 2015
)
0.42
" To understand the pharmacokinetic characteristics of CAPE, the binding interaction between CAPE and human serum albumin (HSA) was investigated in vitro using multiple spectroscopic methods and molecular docking."( Caffeic acid phenethyl ester exhibiting distinctive binding interaction with human serum albumin implies the pharmacokinetic basis of propolis bioactive components.
Hu, F; Li, H; Tan, J; Wang, K; Wu, F; Zhang, C; Zheng, H, 2016
)
0.43
" Dermal pharmacokinetic of CSNPs with a size of 228."( In-vivo dermal pharmacokinetics, efficacy, and safety of skin targeting nanoparticles for corticosteroid treatment of atopic dermatitis.
Amin, MC; Jamil, A; Katas, H; Ng, SF; Siddique, MI; Zulfakar, MH, 2016
)
0.43
" This review summarizes new findings on PhGs over the past 10 years, concerning the new structures, their bioactivities, including neuroprotective, anti-inflammatory, antioxidant, antibacterial and antivirus, cytotoxic, immunomodulatory, and enzyme inhibitory effects, and pharmacokinetic properties."( Phenylethanoid Glycosides: Research Advances in Their Phytochemistry, Pharmacological Activity and Pharmacokinetics.
Xue, Z; Yang, B, 2016
)
0.43
" Thus, the pharmacokinetic characteristics in rat and the gut microbial degradation of tyrosol acyl esters (TYr-Es) with fatty acids of C12:0, C18:0, and C18:2 were investigated for the first time."( Evaluation of Absorption and Plasma Pharmacokinetics of Tyrosol Acyl Esters in Rats.
Hu, Y; Liu, X; Qin, L; Shahidi, F; Wang, X; Xie, H; Yin, F; Zhang, J; Zhou, D, 2020
)
0.56
" Pharmacokinetic analysis was performed through GC-MS to evaluate how quickly it absorbs and distributes in plasma."( Metabolite Profiling, Stability Testing, Pharmacokinetics, and In Vivo Pattern Recognition Analysis of Arq-e-Keora: A Traditional Unani Formulation.
Ahmad, S; Khan, AA; Parveen, A; Parveen, R; Zahiruddin, S, 2022
)
0.72
" Pharmacokinetics data of phenethyl alcohol showed its absorption was rapid, with Tmax occurring within 1 h after oral administration of Arq-e-Keora."( Metabolite Profiling, Stability Testing, Pharmacokinetics, and In Vivo Pattern Recognition Analysis of Arq-e-Keora: A Traditional Unani Formulation.
Ahmad, S; Khan, AA; Parveen, A; Parveen, R; Zahiruddin, S, 2022
)
0.72
"As a result, our model could be used for quality, stability, and pharmacokinetic evaluation of various Unani formulations mentioned in Unani Pharmacopoeia of India."( Metabolite Profiling, Stability Testing, Pharmacokinetics, and In Vivo Pattern Recognition Analysis of Arq-e-Keora: A Traditional Unani Formulation.
Ahmad, S; Khan, AA; Parveen, A; Parveen, R; Zahiruddin, S, 2022
)
0.72
"This is the first study of pharmacokinetic analysis and metabolite pattern of traditional Unani formulation after its oral administration in Wistar rats."( Metabolite Profiling, Stability Testing, Pharmacokinetics, and In Vivo Pattern Recognition Analysis of Arq-e-Keora: A Traditional Unani Formulation.
Ahmad, S; Khan, AA; Parveen, A; Parveen, R; Zahiruddin, S, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" Interestingly, the -N cultivation combined with 2-phenylethanol exposure reduced the Synechocystis protein content by 27% (w/w DW) but significantly increased PHB levels up to 33% (w/w DW), the highest ever reported photoautotrophic cyanobacterial PHB accumulation in a wild-type strain."( Chemicals Affecting Cyanobacterial Poly(3-hydroxybutyrate) Accumulation: 2-Phenylethanol Treatment Combined with Nitrogen Deprivation Synergistically Enhanced Poly(3-hydroxybutyrate) Storage in Synechocystis sp. PCC6803 and Anabaena sp. TISTR8076.
Incharoensakdi, A; Monshupanee, T; Sukkasam, N, 2022
)
0.72
" To achieve the reutilization of the condensate, the ozonation combined with ion-exchange method was used."( Exploring the resourcing technology of condensate using ozonation combined with ion-exchange in ethanol fermentation.
Li, Z; Sheng, X; Zhang, J, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" Despite its relevant biological effects, no data are available on its bioavailability and metabolism."( Transport mechanism and metabolism of olive oil hydroxytyrosol in Caco-2 cells.
Cucciolla, V; D'Angelo, S; Galletti, P; Maisto, G; Manna, C; Zappia, V, 2000
)
0.31
" Bioavailability and metabolism studies of this compound are extremely limited, in part, related to unavailability of radiolabeled compound."( Synthesis of tritium-labeled hydroxytyrosol, a phenolic compound found in olive Oil.
Hayball, PJ; Tan, HW; Tuck, KL, 2000
)
0.31
" One of the prerequisites to extrapolate these data to an in vivo situation is the knowledge of their bioavailability in humans."( Capillary gas chromatography-mass spectrometry quantitative determination of hydroxytyrosol and tyrosol in human urine after olive oil intake.
Covas, MI; de la Torre, R; Farré Albaladejo, M; Lamuela Raventós, RM; Menoyo Colomer, E; Miró-Casas, E; Rodriguez, JO, 2001
)
0.31
" Oral bioavailability estimates of hydroxytyrosol when administered in an olive oil solution and when dosed as an aqueous solution were 99% and 75%, respectively."( The in vivo fate of hydroxytyrosol and tyrosol, antioxidant phenolic constituents of olive oil, after intravenous and oral dosing of labeled compounds to rats.
Freeman, MP; Hayball, PJ; Stretch, GL; Stupans, I; Tuck, KL, 2001
)
0.31
"We have recently demonstrated, in humans, the bioavailability of hydroxytyrosol (3,4-dihydroxyphenylethanol; HT), one of the major antioxidant components of virgin olive oil."( Urinary excretion of olive oil phenols and their metabolites in humans.
Caruso, D; Galli, C; Galli, G; Patelli, R; Visioli, F, 2001
)
0.31
" We have demonstrated the bioavailability of tyrosol in humans from virgin olive oil in its natural form."( Bioavailability of tyrosol, an antioxidant phenolic compound present in wine and olive oil, in humans.
Covas, MI; De La Torre, R; Farré-Albadalejo, M; Fitó, M; Gimeno, E; Marrugat, J; Miró-Casas, E, 2003
)
0.32
" Hydroxytyrosol is well absorbed in the gastrointestinal tract but its bioavailability is poor because an important first past metabolism both in gut and liver, leading to the formation of sulphate and glucuronide conjugates, to the extent that concentrations in body fluids of its free form are almost undetectable."( Bioavailability of olive oil phenolic compounds in humans.
de la Torre, R, 2008
)
0.35
" Their bioavailability in humans is poor, and they are found in biological fluids mainly as conjugated metabolites."( Antioxidant activities of hydroxytyrosol main metabolites do not contribute to beneficial health effects after olive oil ingestion.
Covas, MI; de la Torre, R; Farré, M; Fitó, M; Joglar, J; Khymenets, O; Muñoz-Aguayo, D; Pujadas, M; Torres, JL; Touriño, S, 2010
)
0.36
" The bioavailability of TG in rats is 27."( A rapid determination of drug candidate tyrosol galactoside in rat plasma by HPLC and its application to the pharmacokinetics study.
Deng, Y; Li, X; Liu, X; Shi, T; Sun, X; Wang, Q; Wang, Y; Zhou, D, 2011
)
0.37
" The method has been successfully applied to the pharmacokinetic study and the oral bioavailability was calculated."( Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry.
Fan, X; Guo, N; Hu, Z; Li, H; Wang, Y; Xu, T; Yu, T; Zhang, D; Zheng, J, 2012
)
0.38
" The good bioavailability by the oral route and good historical safety profile makes propolis an ideal adjuvant agent for future immunomodulatory or anticancer regimens."( The immunomodulatory and anticancer properties of propolis.
Chan, GC; Cheung, KW; Sze, DM, 2013
)
0.39
" CADPE was quickly hydrolyzed both in mice and in vitro mice plasma, but was much stable in vitro human plasma, suggesting a better bioavailability of CADPE in human than in mice."( Antitumor activity of caffeic acid 3,4-dihydroxyphenethyl ester and its pharmacokinetic and metabolic properties.
Guo, X; He, Q; Lian, XY; Shen, L; Tong, Y; Wu, G; Ye, X; Yu, S; Zhang, J; Zhang, Z; Zou, L, 2013
)
0.39
" To quantify the bioavailability and metabolism of oleuropein and hydroxytyrosol when taken as OLE, nine volunteers (five males) aged 42."( Human absorption and metabolism of oleuropein and hydroxytyrosol ingested as olive (Olea europaea L.) leaf extract.
Cutfield, WS; de Bock, M; Derraik, JG; Henderson, HV; Hofman, PL; Thorstensen, EB, 2013
)
0.39
" Further studies are needed to determine the bioavailability of these compounds and their possible beneficial health effects when taken by moderate beer consumption."( Beer and beer compounds: physiological effects on skin health.
Becker, T; Chen, W; Qian, F; Ring, J, 2014
)
0.4
" Hydroxytyrosol is an orally bioavailable polyphenol, obtained from olives, which inhibits NF-κβ activity and has elicited promising efficacy signals in several inflammatory diseases."( NF-κβ signaling and chronic inflammatory diseases: exploring the potential of natural products to drive new therapeutic opportunities.
Crea, R; Killeen, MJ; Linder, M; Pontoniere, P, 2014
)
0.4
" In this review HT bioavailability and pharmacokinetics are presented prior to discussing health beneficial effects."( Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases.
de la Torre, R; Dierssen, M; Farré, M; Fitó, M; Rodríguez-Morató, J; Xicota, L, 2015
)
0.42
"The notion that (poly)phenols act as direct free radical scavengers is being challenged by mere chemical and biochemical considerations such as bioavailability and intracellular concentrations."( One-week administration of hydroxytyrosol to humans does not activate Phase II enzymes.
Burgos-Ramos, E; Crespo, MC; Espinosa, MI; Herranz, J; Loria Kohen, V; Tomé-Carneiro, J; Visioli, F,
)
0.13
" BCS1 classification was leveraged throughout development to assess the risk associated with not conducting relative bioavailability (RBA) studies and avoiding bioequivalence (BE) studies."( Leveraging BCS in Development: A Case Study.
Aburub, A; Fadda, HM; Hoaglund Hyzer, CS; Rodriguez, JO, 2015
)
0.42
" However, the bioavailability of the most important of these compounds, hydroxytyrosol (HT), and its transformation into derivatives within the organism after oral intake are still not completely understood, requiring further in vivo research."( Gender differences in plasma and urine metabolites from Sprague-Dawley rats after oral administration of normal and high doses of hydroxytyrosol, hydroxytyrosol acetate, and DOPAC.
Auñón, D; Domínguez-Perles, R; Ferreres, F; Gil-Izquierdo, A, 2017
)
0.46
"Plasma and urine levels indicated that although the three compounds are efficiently absorbed in the gastrointestinal tract and show similar metabolism, the bioavailability is strongly dependent on the derivative considered, dosage, and gender."( Gender differences in plasma and urine metabolites from Sprague-Dawley rats after oral administration of normal and high doses of hydroxytyrosol, hydroxytyrosol acetate, and DOPAC.
Auñón, D; Domínguez-Perles, R; Ferreres, F; Gil-Izquierdo, A, 2017
)
0.46
" In conclusion, NO2HT, NO2HT-A, and NO2HT-E show high in vitro bioavailability and are extensively metabolized by hepatic cells."( Evaluation of the Bioavailability and Metabolism of Nitroderivatives of Hydroxytyrosol Using Caco-2 and HepG2 Human Cell Models.
Bravo-Clemente, L; Espartero, JL; Gallardo, E; Gonzalez Correa, JA; Mateos, R; Sarria, B, 2016
)
0.43
" We performed a crossover, randomized, double-blind study to evaluate HT bioavailability in HT-enriched biscuits (HT-B) versus non-enriched biscuits (C-B), and the effects on oxidative postprandial status."( Hydroxytyrosol in functional hydroxytyrosol-enriched biscuits is highly bioavailable and decreases oxidised low density lipoprotein levels in humans.
Amigo-Benavent, M; Baeza Arévalo, G; Bravo-Clemente, L; Martínez-López, S; Mateos, R; Sarriá, B, 2016
)
0.43
" In this regard, information regarding the bioavailability and metabolic disposition of hydroxytyrosol and tyrosol is of most importance to evaluate the impact they may have on human health."( Metabolic disposition and biological significance of simple phenols of dietary origin: hydroxytyrosol and tyrosol.
Boronat, A; de la Torre, R; Farré, M; Fitó, M; Khymenets, O; Kotronoulas, A; Olesti, E; Pastor, A; Pérez-Mañá, C; Pujadas, M; Rodríguez-Morató, J, 2016
)
0.43
" In addition, it is suggested that CAPE-NPs can be used to reduce the dosage of CAPE and improve their bioavailability and thus merit further investigation for bioactive packaging film and coating applications."( Fabrication of Novel Bioactive Cellulose-Based Films Derived from Caffeic Acid Phenethyl Ester-Loaded Nanoparticles via a Rapid Expansion Process: RESOLV.
Assatarakul, K; Saelo, S; Sane, A; Suppakul, P, 2016
)
0.43
" The bioavailability and bioactivity was evaluated following gavage with HT/PCy in rabbits."( Olive and grape seed extract prevents post-traumatic osteoarthritis damages and exhibits in vitro anti IL-1β activities before and after oral consumption.
Abadie, J; Beck, L; Gauthier, O; Guicheux, J; Hivernaud, V; Houard, X; Krisa, S; Lesoeur, J; Masson, M; Merceron, C; Mével, E; Nourissat, G; Richard, T; Urban, N; Vinatier, C; Wittrant, Y, 2016
)
0.43
" Moreover, we also discuss the chemistry, nutritional aspects and bioavailability of hydroxytyrosol."( Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil.
Del Mar Bibiloni, M; Pinya, S; Pons, A; Sureda, A; Tejada, S; Tur, JA, 2017
)
0.46
" In addition the concentration, metabolism and bioavailability of specific phenolic compounds will be discussed."( The Health Benefiting Mechanisms of Virgin Olive Oil Phenolic Compounds.
Cicerale, S; Parkinson, L, 2016
)
0.43
" This study attempted to prepare liposomes containing water-soluble HT to improve the bioavailability and biocompatibility of the target drug."( Preparation, Characterization, and Antioxidant Activity Evaluation of Liposomes Containing Water-Soluble Hydroxytyrosol from Olive.
Li, B; Qin, FGF; Tu, JL; Yuan, JJ, 2017
)
0.46
" Bioavailability studies show that the metabolites detected in plasma depend on the model used (animal or human), the HT source (simple molecule or complex precursors) and the dose administered."( Hydroxytyrosol: Emerging Trends in Potential Therapeutic Applications.
de Las Hazas, MCL; Macia, A; Motilva, MJ; Rubio, L, 2018
)
0.48
" In this work, Zn and Se bioavailability was increased in chicken meat emulsions that are enriched with Hydroxytyrosol (HXT), a phenolic compound obtained from olive leaf."( Fe, Zn and Se Bioavailability in Chicken Meat Emulsions Enriched with Minerals, Hydroxytyrosol and Extra Virgin Olive Oil as Measured by Caco-2 Cell Model.
Martínez, L; Nieto, G; Ros, G, 2018
)
0.48
" Caffeic acid phenethyl ester (CAPE) and piceatannol (PIC) are natural anti-inflammatory compounds; however, poor bioavailability and limited understanding of biomolecular mechanistic limits its clinical use."( Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NF-kB pathways and improves therapeutic outcome in experimental colitis.
Khan, MN; McCarron, PA; Tambuwala, MM; Thompson, P, 2019
)
0.51
" These natural antioxidants molecules revealed several beneficial effects on human health, but a low bioavailability and accessibility to targeted site."( Chemical characterization of liposomes containing nutraceutical compounds: Tyrosol, hydroxytyrosol and oleuropein.
Bonechi, C; Consumi, M; Donati, A; Lamponi, S; Leone, G; Magnani, A; Pardini, A; Rossi, C; Rostom, H; Tamasi, G, 2019
)
0.51
"Acrylamide and phenolic compounds on both fresh and cooked olives were monitored by HPLC/MS-MS and reversed-phase-HPLC methods along different procedures: elaboration process, high hydrostatic pressure (HHP), cooking treatment and bioavailability evaluation."( Monitoring of acrylamide and phenolic compounds in table olive after high hydrostatic pressure and cooking treatments.
Cabrera-Bañegil, M; Delgado-Adámez, J; Fernández, A; Lodolini, EM; Martín-Vertedor, D; Ramírez, R, 2019
)
0.51
" This review summarizes recent findings regarding biological activities, metabolism and bioavailability of the major olive oil phenolic compounds-hydroxytyrosol, tyrosol, oleuropein, oleocanthal and oleacein-the most important being their antiatherogenic, cardioprotective, anticancer, neuroprotective and endocrine effects."( Hydroxytyrosol, Tyrosol and Derivatives and Their Potential Effects on Human Health.
Barbarić, M; Jakobušić Brala, C; Karković Marković, A; Torić, J, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Nevertheless, some knowledge gaps remain on its bioavailability and metabolism; overall concerning to the real rate per cent of absorption and biovailability of dietary hydroxytyrosol and the influence of the dietary food-containing hydroxytyrosol on it."( Pharmacokinetics and bioavailability of hydroxytyrosol are dependent on the food matrix in humans.
Alemán-Jiménez, C; Auñón, D; Campillo-Cano, M; Domínguez-Perles, R; Ferreres, F; Gil-Izquierdo, Á; López-González, I; Medina, S; Prgomet, I; Simonelli-Muñoz, A, 2021
)
0.62
"A double-blind study was performed including 20 volunteers who ingested 5 mg of hydroxytyrosol through diverse food matrices, to discover the influence on pharmacokinetics and bioavailability of HT metabolites (hydroxytyrosol acetate, 3,4-dihydroxyphenylacetic acid (DOPAC), tyrosol, and homovanillic alcohol) of the distinct matrices by UHPLC-ESI-QqQ-MS/MS."( Pharmacokinetics and bioavailability of hydroxytyrosol are dependent on the food matrix in humans.
Alemán-Jiménez, C; Auñón, D; Campillo-Cano, M; Domínguez-Perles, R; Ferreres, F; Gil-Izquierdo, Á; López-González, I; Medina, S; Prgomet, I; Simonelli-Muñoz, A, 2021
)
0.62
"The metabolic profile of hydroxytyrosol is influenced by the food matrix in which is incorporated, with the oily nature for the final bioavailability being relevant."( Pharmacokinetics and bioavailability of hydroxytyrosol are dependent on the food matrix in humans.
Alemán-Jiménez, C; Auñón, D; Campillo-Cano, M; Domínguez-Perles, R; Ferreres, F; Gil-Izquierdo, Á; López-González, I; Medina, S; Prgomet, I; Simonelli-Muñoz, A, 2021
)
0.62
" However, they have low bioavailability due to their low absorption and high metabolism in human liver and small intestine."( De novo biosynthesis of tyrosol acetate and hydroxytyrosol acetate from glucose in engineered Escherichia coli.
Fu, X; Guo, D; Li, X; Pan, H; Sun, Y, 2021
)
0.62
"Many studies have shown that caffeic acid phenethyl ester (CAPE) has various functions, such as antioxidant, anti-inflammatory and anticancer activity, but its low bioavailability and stability limit its application."( Caffeic acid phenethyl ester loaded in a targeted delivery system based on a solid-in-oil-in-water multilayer emulsion: Characterization, stability, and fate of the emulsion during in vivo digestion.
Chen, P; Chen, X; Dai, J; Du, Y; Huang, Y; Li, R; Liu, L; Wang, L; Wang, Q; Wang, Z; Wei, X; Yang, X; Zhou, Z, 2022
)
0.72
" However, extremely low absorption rate of olive phenolic compounds restricts their bioactivity."( Hydroxytyrosol oleate: A promising neuroprotective nanocarrier delivery system of oleuropein and derivatives.
Brocchini, S; Nardi, M; Procopio, A; Somavarapu, S, 2023
)
0.91
" Bioavailability studies with olive oils showed that HT is bioavailable from its free form and from conjugated forms such as oleuropein and its aglycone."( Oral Bioavailability and Metabolism of Hydroxytyrosol from Food Supplements.
Bender, C; Golz, C; Strassmann, S, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" For both compounds, the intravenously and orally administered oil-based dosings resulted in significantly greater elimination of the phenolics in urine within 24 h than the oral, aqueous dosing method."( The in vivo fate of hydroxytyrosol and tyrosol, antioxidant phenolic constituents of olive oil, after intravenous and oral dosing of labeled compounds to rats.
Freeman, MP; Hayball, PJ; Stretch, GL; Stupans, I; Tuck, KL, 2001
)
0.31
" Recently it was shown that hydroxytyrosol and five metabolites were excreted in urine when hydroxytyrosol was dosed intravenously or orally in an olive oil solution to rats."( Structural characterization of the metabolites of hydroxytyrosol, the principal phenolic component in olive oil, in rats.
Hayball, PJ; Stupans, I; Tuck, KL, 2002
)
0.31
" Studies of olfaction did not support unusual sensitivity, defined as lower odor thresholds, among MCS subjects; however, a dose-response pattern of symptoms was observed in response to suprathreshold concentrations of phenyl ethyl alcohol."( Controlled exposures to volatile organic compounds in sensitive groups.
Fiedler, N; Kipen, HM, 2001
)
0.31
" The results showed that methyl jasmonate and salicylic acid enhanced greatly the accumulation of PeG and echinacoside (Echin), but their optimum elicitation dosage and addition time were different."( [Effects of methyl jasmonate and salicylic acid on phenylethanoid glycosides synthesis in suspension cultures of Cistanche deserticola].
Chen, YQ; Fu, CX; Jin, ZP; Xu, LS; Xue, XF; Zhao, DX, 2005
)
0.33
" More studies are needed to determine the optimal administration route and effective dosage of this compound."( Effect of caffeic acid phenethyl ester on treatment of experimentally induced methicillin-resistant Staphylococcus epidermidis endophthalmitis in a rabbit model.
Adigüzel, U; Arpaci, R; Aslan, G; Cinel, L; Emekdaş, G; Kanik, A; Oz, O; Tamer, L; Vatansever, H; Yildirim, O; Yilmaz, A,
)
0.13
" In addition, the dose-response curves of KCl (2."( The vasorelaxant effect of caffeic acid phenethyl ester on porcine coronary artery ring segments.
Chen, J; Chen, Q; Han, M; Long, Y; Tian, XZ; Wang, R,
)
0.13
"-administered at a dosage of 10 µmol/kg, it enhanced the recovery of locomotor function and reduced the lesion size while suppressing the expression of the mRNAs for a pro-inflammatory cytokine interleukin-1β and the inflammatory enzymes, inducible nitric oxide synthase and cyclooxygenase-2."( Caffeic acid phenethyl ester reduces spinal cord injury-evoked locomotor dysfunction.
Fukumitsu, H; Furukawa, S; Kasai, M; Soumiya, H, 2011
)
0.37
" In this report, it was observed that combined treatment of a low dosage of curcumin (5-10 µM) with a low concentration (0."( Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells.
Chuu, CP; Kuo, LK; Lin, HP, 2012
)
0.38
" We observed that CAPE dosage dependently suppressed the proliferation of LNCaP, DU-145, and PC-3 human prostate cancer cells."( Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks.
Chuu, CP; Ciaccio, MF; Hause, RJ; Hiipakka, RA; Jones, RB; Kokontis, JM; Liao, S; Lin, HP, 2012
)
0.38
" The PK and PD data inform edivoxetine pharmacology and can be used to develop comprehensive population PK and/or PK-PD models to guide dosing strategies."( Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder.
Allen, AJ; Dean, RA; Jin, L; Kielbasa, W; Lachno, DR; Quinlan, T; Xu, W, 2012
)
0.38
" Absorption, distribution, metabolism, and excretion were compared following topical application of ¹⁴C-labeled PEA to rats, rabbits, and humans (specific activities of dosing solutions: 58-580, 164, and 50 µCi/mL, respectively)."( The pharmacokinetics of phenylethyl alcohol (PEA): safety evaluation comparisons in rats, rabbits, and humans.
Api, AM; Christian, MS; Diener, RM; Hawkins, DR; Politano, VT; Ritacco, G,
)
0.44
" Daily dosing of edivoxetine in a larger population of impaired subjects, including those with dual impairment, would aid in establishing edivoxetine tolerability and PK in a clinical practice scenario."( The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.
Kielbasa, W; Luffer-Atlas, D; Mitchell, MI; Tesfaye, E; Turik, MA, 2013
)
0.39
" Dose-response and time-dependence studies were carried out."( Hydroxytyrosol and oleuropein of olive oil inhibit mast cell degranulation induced by immune and non-immune pathways.
Fogal, TH; Mariani, ML; Penissi, AB; Persia, FA, 2014
)
0.4
"The aims of this study were to determine the efficacy and tolerability of different dosages of, and to identify the best dosage of, tratinterol hydrochloride tablets in the treatment of bronchial asthma."( Efficacy and tolerability of tratinterol hydrochloride tablets in bronchial asthma: a multicenter, randomized, double-blind, dose-finding clinical trial.
Kang, J; Kong, L; Liu, J; Shao, Y; Sun, S; Yuan, Y, 2014
)
0.4
" In terms of the primary and secondary end points, the intermediate dosage was most efficacious, followed by the high and low dosages, respectively."( Efficacy and tolerability of tratinterol hydrochloride tablets in bronchial asthma: a multicenter, randomized, double-blind, dose-finding clinical trial.
Kang, J; Kong, L; Liu, J; Shao, Y; Sun, S; Yuan, Y, 2014
)
0.4
"In these patients with bronchial asthma, 100 μg/d was the dosage of tratinterol hydrochloride tablets most efficacious in terms of improvement in lung function."( Efficacy and tolerability of tratinterol hydrochloride tablets in bronchial asthma: a multicenter, randomized, double-blind, dose-finding clinical trial.
Kang, J; Kong, L; Liu, J; Shao, Y; Sun, S; Yuan, Y, 2014
)
0.4
" The 15% HT formulated extract did not induce micronuclei in rat bone marrow after 4 weeks of dosing up to 561 mg HT/kg/day."( Investigations into the genotoxic potential of olive extracts.
Beilstein, P; Edwards, J; Kirkland, D; Woehrle, T, 2015
)
0.42
"Adult outpatients with MDD who were partial responders to SSRI treatment (N = 1249) entered an open-label 8 week flexibly dosed (12-18 mg/day) adjunctive edivoxetine period."( Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Ahl, J; Dellva, MA; Goldberger, C; Greenbaum, M; Oakes, TM; Perahia, DG; Poppe, C; Waterman, K, 2015
)
0.42
" This method has the advantages of simple process and operation, less dosage of organic solvent, highly yield and reproducibility, suitable for the simultaneously preparation of tyrosol, crenulatin and salidroside."( [Simultaneously preparation of grams of high purity tyrosol, crenulatin and salidroside from Rhodiola crenulata].
Li, SP; Luo, X; Wang, XJ; Wang, ZZ; Xiao, W; Zhang, Q; Zhao, YW, 2015
)
0.42
"Fluticasone propionate (FLU) and Azelastine hydrochloride (AZE) are co-formulated with phenylethyl alcohol (PEA) and Benzalkonium chloride (BENZ) (as preservatives) in pharmaceutical dosage form for treatment of seasonal allergies."( Simultaneous determination of Fluticasone propionate and Azelastine hydrochloride in the presence of pharmaceutical dosage form additives.
El-Mosallamy, SS; El-Zeany, BA; Hassan, NY; Merey, HA, 2016
)
0.66
" With extraction rate of salidroside, tyrosol, crenulatin and gallic acid as indexes, orthogonal test was used to evaluate effect of 4 factors on extracting technology, including concentration of solvent, the dosage of solvent, duration of extraction, and frequency of extraction."( [Optimization of extraction technology for salidroside, tyrosol, crenulatin and gallic acid in Rhodiolae Crenulatae Radix et Rhizoma with orthogonal test].
Huang, WZ; Luo, X; Wang, XJ; Wang, ZZ; Xiao, W; Zhao, YW, 2015
)
0.42
" In addition, it is suggested that CAPE-NPs can be used to reduce the dosage of CAPE and improve their bioavailability and thus merit further investigation for bioactive packaging film and coating applications."( Fabrication of Novel Bioactive Cellulose-Based Films Derived from Caffeic Acid Phenethyl Ester-Loaded Nanoparticles via a Rapid Expansion Process: RESOLV.
Assatarakul, K; Saelo, S; Sane, A; Suppakul, P, 2016
)
0.43
" HT was administered at a daily dosage of 45mg for 8 weeks to volunteers with mild hyperlipidemia (n=14)."( Hydroxytyrosol supplementation increases vitamin C levels in vivo. A human volunteer trial.
Fonolla, J; Lopez-Huertas, E, 2017
)
0.46
"This was an open-label study of edivoxetine once daily dosing (0."( Long-Term, Open-Label, Safety Study of Edivoxetine Monotherapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Ahl, J; Bangs, M; Liu, P; Nery, ESM; Perahia, D, 2017
)
0.46
" A dose-response model in combination with a Markov-chain monte-carlo (MCMC) method for Bayesian inference was used to estimate and compare performance in terms of error rates involved in the detection of insect responses to GC peaks visible on an FID detector."( Increasing Signal-to-Noise Ratio in Gas Chromatography - Electroantennography Using a Deans Switch Effluent Chopper.
Baker, TC; Myrick, AJ, 2018
)
0.48
" The effects of substrate concentration, temperature, pH, time, and enzyme dosage on the concentration of TF produced are studied using the design of experiments methodology."( Screening of Commercial Enzymes for Transfructosylation of Tyrosol: Effect of Process Conditions and Reaction Network.
Antošová, M; Hollá, V; Karkeszová, K; Mastihuba, V; Polakovič, M, 2019
)
0.51
" The increase in the cytotoxicity was dependent on the CAPE dosage (50 vs."( Caffeic Acid Phenethyl Ester (CAPE) Synergistically Enhances Paclitaxel Activity in Ovarian Cancer Cells.
Dzik, R; Kabała-Dzik, A; Kleczka, A, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (96 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care95
Household Essentials1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Acure Resurfacing Glycolic + Unicorn Root Cleanser -- 4 fl ozAcureBeauty & Personal Careglyceryl oleate, decyl glucoside, ethylhexylglycerin, glycerin, glycolic acid, hemp, lactic acid, glyceryl caprylate, phenethyl alcohol2024-11-29 10:47:42
Acure Resurfacing Overnight Glycolic Treatment -- 1 fl ozAcureBeauty & Personal Carecitric acid, cetyl alcohol, citric acid, tocopherol, ethylhexylglycerin, tocopherol, glyceryl stearate, glycerin, glycolic acid, hemp, lactic acid, glyceryl laurate, phenethyl alcohol2024-11-29 10:47:42
Acure Seriously Soothing Cleansing Cream -- 4 fl ozAcureBeauty & Personal Carecaprylyl glycol, glyceryl oleate, chamomile, calendula, decyl glucoside, ethylhexylglycerin, glycerin, glyceryl caprylate, phenethyl alcohol2024-11-29 10:47:42
Acure Ultra Hydrating 12 Hour Facial Moisturizer -- 1 fl ozAcureBeauty & Personal Careorange, geranium, cetearyl alcohol, cetyl alcohol, tocopherol, ethylhexylglycerin, tocopherol, glycerin, glyceryl laurate, glyceryl caprylate, phenethyl alcohol2024-11-29 10:47:42
Acure Ultra Hydrating Eye Cream -- 0.5 fl ozAcureBeauty & Personal Carecitric acid, cetyl alcohol, citric acid, tocopherol, ethylhexylglycerin, tocopherol, glyceryl stearate, glycerin, glyceryl laurate, phenethyl alcohol2024-11-29 10:47:42
Acure Ultra Hydrating Green Juice Cleanser -- 4 fl ozAcureBeauty & Personal Careglyceryl oleate, orange, decyl glucoside, ethylhexylglycerin, glycerin, glyceryl caprylate, phenethyl alcohol2024-11-29 10:47:42
Alba Botanica Very Emollient Body Lotion Daily Shade SPF 15 -- 32 fl ozAlbaBeauty & Personal Careamyl cinnamal, citric acid, allantoin, ascorbic acid, benzoic acid, cetearyl alcohol, cetyl alcohol, citric acid, dehydroacetic acid, panthenol, triethyl citrate, geraniol, glycerin, glycolic acid, dimethicone, lactic acid, limonene, phenoxyethanol, phenethyl alcohol, potassium hydroxide, sodium benzoate2024-11-29 10:47:42
Andalou Naturals 1000 Roses Daily Shade Facial Lotion SPF 18 -- 2.7 fl ozAndalou NaturalsBeauty & Personal Careoctisalate, orange, allantoin, chamomile, vitamin C, cetyl alcohol, tocopherol, panthenol, ethylhexylglycerin, tocopherol, dimethicone, octocrylene, phenethyl alcohol, stearic acid, stearyl alcohol2024-11-29 10:47:42
Andalou Naturals 1000 Roses Soothing Sleep Mask -- 1.7 fl ozAndalou NaturalsBeauty & Personal Carebutylene glycol, citric acid, citric acid, ethylhexylglycerin, glycerin, phenethyl alcohol, sodium benzoate, squalane2024-11-29 10:47:42
Andalou Naturals A Path of Light Hand Cream Clementine -- 3.4 fl ozAndalou NaturalsBeauty & Personal Careorange, allantoin, cetyl alcohol, tocopherol, ethylhexylglycerin, tocopherol, palmarosa, glyceryl stearate, phenethyl alcohol, stearic acid, stearyl alcohol2024-11-29 10:47:42
Andalou Naturals A Path of Light Hand Cream Lime Blossom -- 3.4 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, Cetyl Alcohol, Tocopherol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Stearic Acid, Stearyl Alcohol2024-11-29 10:47:42
Andalou Naturals Age Defying Apricot Probiotic Cleansing Milk -- 6 fl ozAndalou NaturalsBeauty & Personal Careorange, allantoin, cetyl alcohol, CoQ10, tocopherol, ethylhexylglycerin, tocopherol, vitamin e, glyceryl stearate, glyceryl monolaurate, phenethyl alcohol, resveratrol, ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying Argan Stem Cell Conditioner -- 11.5 fl ozAndalou NaturalsBeauty & Personal CareBiotin, Cetyl Alcohol, Cysteine, Panthenol, Ethylhexylglycerin, Glyceryl Stearate, Niacin, Phenethyl Alcohol, Pyridoxine, Riboflavin, Stearyl Alcohol, Thiamine2024-11-29 10:47:42
Andalou Naturals Age Defying Argan Stem Cell Scalp Intensive -- 2.1 fl ozAndalou NaturalsBeauty & Personal CareBiotin, Cysteine, Panthenol, Ethylhexylglycerin, Niacin, Phenethyl Alcohol, Pyridoxine, Riboflavin, Thiamine2024-11-29 10:47:42
Andalou Naturals Age Defying Deep Wrinkle Dermal Filler -- 0.6 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, Vitamin C, Cetyl Alcohol, CoQ10, Tocopherol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Resveratrol, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying DIY Booster Facial Serum SPF 30 Unscented -- 2 fl ozAndalou NaturalsBeauty & Personal CareCetyl Alcohol, CoQ10, Ethylhexylglycerin, Phenethyl Alcohol, Resveratrol, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying Fruit Stem Cell Revitalize Serum -- 1.1 fl ozAndalou NaturalsBeauty & Personal CareOrange, Allantoin, Vitamin C, Kelp, Cetyl Alcohol, CoQ10, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Melatonin, Glyceryl Laurate, Phenethyl Alcohol, Resveratrol, Riboflavin, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying Goji Peptide Perfecting Cream -- 1.7 ozAndalou NaturalsBeauty & Personal CareOrange, Allantoin, Vitamin C, Bisabolol, Cetyl Alcohol, CoQ10, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Glyceryl Laurate, Phenethyl Alcohol, Resveratrol, Riboflavin, Stearic Acid, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying Toning Refresher Blossom + Leaf -- 6 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, Vitamin C, CoQ10, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Phenethyl Alcohol, Resveratrol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying Ultra Sheer Daily Defense Facial Lotion SPF 18 -- 2.7 fl ozAndalou NaturalsBeauty & Personal CareOrange, Allantoin, Chamomile, Vitamin C, Kelp, Cetyl Alcohol, CoQ10, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Dimethicone, Phenethyl Alcohol, Resveratrol, Stearic Acid, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Brighten & Tighten Hydro Serum Facial Sheet Mask -- 6 fl ozAndalou NaturalsBeauty & Personal Careallantoin, vitamin C, bisabolol, tocopherol, ethylhexylglycerin, tocopherol, vitamin E, phenethyl alcohol2024-11-29 10:47:42
Andalou Naturals Brightening Clementine + C Illuminating Toner -- 6 fl ozAndalou NaturalsBeauty & Personal CareOrange, Allantoin, Vitamin C, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Palmarosa, Phenethyl Alcohol2024-11-29 10:47:42
Andalou Naturals Brightening Creamy Cleanser Meyer Lemon + C -- 6 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, Vitamin C, Cetyl Alcohol, Cocamidopropyl Betaine, Tocopherol, and, Panthenol, Ethylhexylglycerin, Tocopherol, Phenethyl Alcohol, Sorbitol, Stearic Acid, Stearyl Alcohol2024-11-29 10:47:42
Andalou Naturals Brightening Luminous Eye Serum -- 0.6 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, Chamomile, Vitamin C, Kelp, Caffeine, Cetyl Alcohol, Tocopherol, Ethylhexylglycerin, Tocopherol, Phenethyl Alcohol, Stearyl Alcohol2024-11-29 10:47:42
Andalou Naturals Brightening Purple Carrot + C Luminous Night Cream -- 1.7 fl ozAndalou NaturalsBeauty & Personal CareOrange, Allantoin, Vitamin C, Cetyl Alcohol, Tocopherol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Riboflavin, Stearyl Alcohol2024-11-29 10:47:42
Andalou Naturals Brightening Renewal Cream Brightening Probiotic + C -- 1.7 fl ozAndalou NaturalsBeauty & Personal CareOrange, Allantoin, Vitamin C, Cetyl Alcohol, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Stearic Acid2024-11-29 10:47:42
Andalou Naturals Brilliant Shine Conditioner Sunflower and Citrus -- 11.5 fl ozAndalou NaturalsBeauty & Personal CareOrange, Chamomile, Cetyl Alcohol, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Stearyl Alcohol2024-11-29 10:47:42
Andalou Naturals Clear Skin Willow Bark Pure Pore Toner -- 6 fl ozAndalou NaturalsBeauty & Personal CareVitamin C, Camphor, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Phenethyl Alcohol, Salicylic Acid2024-11-29 10:47:42
Andalou Naturals Color Care 1000 Roses Shampoo -- 11.5 fl ozAndalou NaturalsBeauty & Personal Careorange, cocamidopropyl betaine, tocopherol, and, ethylhexylglycerin, tocopherol, phenethyl alcohol, sodium lauroyl sarcosinate2024-11-29 10:47:42
Andalou Naturals Firming Body Butter Lavender Shea -- 8 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, CoQ10, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Stearic Acid, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Hand Cream Lavender Shea -- 3.4 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, Cetyl Alcohol, Tocopherol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Stearic Acid, Stearyl Alcohol2024-11-29 10:47:42
Andalou Naturals Hyaluronic DMAE Lift & Firm Cream Age Defying -- 1.7 ozAndalou NaturalsBeauty & Personal Careorange, allantoin, vitamin C, bisabolol, CoQ10, tocopherol, dimethylaminoethanol, panthenol, ethylhexylglycerin, tocopherol, glyceryl stearate, phenethyl alcohol, resveratrol, riboflavin, ubiquinone2024-11-29 10:47:42
Andalou Naturals Moisture Rich Conditioner Argan Oil & Shea -- 11.5 fl ozAndalou NaturalsBeauty & Personal CareOrange, Arginine, Cetyl Alcohol, Tocopherol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Serine, Stearyl Alcohol, Threonine2024-11-29 10:47:42
Andalou Naturals Nourishing Body Butter Kukui Cocoa -- 8 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Stearic Acid, Stearyl Alcohol2024-11-29 10:47:42
Andalou Naturals Pure Pore Hydro Serum Facial Sheet Mask -- 0.6 fl ozAndalou NaturalsBeauty & Personal Careallantoin, bisabolol, tocopherol, tocopherol, palmarosa, vitamin E, phenethyl alcohol2024-11-29 10:47:42
Andalou Naturals Refreshing Body Lotion Lavender and Thyme -- 8 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, Cetyl Alcohol, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Stearic Acid2024-11-29 10:47:42
Andalou Naturals Resveratrol Q10 Night Repair Cream -- 1.7 fl ozAndalou NaturalsBeauty & Personal Careallantoin, vitamin c, cetyl alcohol, coq10, comfrey, tocopherol, ethylhexylglycerin, tocopherol, glyceryl stearate, phenethyl alcohol, resveratrol, riboflavin, stearyl alcohol, ubiquinone2024-11-29 10:47:42
Andalou Naturals Soothing Body Lotion 1000 Roses -- 8 fl ozAndalou NaturalsBeauty & Personal CareOrange, Allantoin, Cetyl Alcohol, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Stearic Acid2024-11-29 10:47:42
Andalou Naturals Uplifting Body Lotion Citrus Sunflower -- 8 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, Cetyl Alcohol, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Stearic Acid2024-11-29 10:47:42
Andalou Naturals Velvet Soft 1000 Roses Body Butter -- 8 fl ozAndalou NaturalsBeauty & Personal Careorange, allantoin, tocopherol, panthenol, ethylhexylglycerin, tocopherol, glyceryl stearate, phenethyl alcohol, stearic acid, stearyl alcohol2024-11-29 10:47:42
Andalou Naturals Vitalizing Body Lotion Mandarin Vanilla -- 8 fl ozAndalou NaturalsBeauty & Personal CareOrange, Allantoin, Cetyl Alcohol, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Stearic Acid2024-11-29 10:47:42
Avalon Organics Wrinkle Therapy Cleansing Milk -- 8.5 fl ozAvalon OrganicsBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, citronellol, CoQ10, geraniol, glycerin, phenethyl alcohol, potassium hydroxide, ribose, sodium benzoate, sorbitol, stearic acid, ubiquinone2024-11-29 10:47:42
Avalon Organics Wrinkle Therapy Day Cream -- 1.75 ozAvalon OrganicsBeauty & Personal CareCetyl Alcohol, Citral, Citronellol, CoQ10, Geraniol, Glyceryl Stearate, Glycerin, Phenethyl Alcohol, Ribose, Sodium Benzoate, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Avalon Organics Wrinkle Therapy Facial Serum -- 0.55 fl ozAvalon OrganicsBeauty & Personal Carecetyl alcohol, citral, citronellol, CoQ10, geraniol, glyceryl stearate, phenethyl alcohol, ribose, sodium benzoate, squalane, ubiquinone2024-11-29 10:47:42
Avalon Organics Wrinkle Therapy Firming Body Lotion with CoQ10 & Rosehip -- 8 fl ozAvalon OrganicsBeauty & Personal CareBenzyl Alcohol, Bisabolol, Cetyl Alcohol, Citral, Citronellol, CoQ10, Geraniol, Glycerin, Phenethyl Alcohol, Potassium Hydroxide, Ribose, Sodium Benzoate, Stearic Acid, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Babe Original Brow Volumizing Brow Filler Dark Brown -- 0.12 ozBabe OriginalBeauty & Personal Carecitric acid, biotin, citric acid, panthenol, glyceryl stearate, glycerin, glyceryl caprylate, phenethyl alcohol, sodium benzoate, titanium dioxide2024-11-29 10:47:42
Babe Original Brow Volumizing Brow Filler Taupe -- 0.12 ozBabe OriginalBeauty & Personal Carecitric acid, biotin, citric acid, panthenol, glyceryl stearate, glycerin, glyceryl caprylate, phenethyl alcohol, sodium benzoate, titanium dioxide2024-11-29 10:47:42
Babe Original Densifying Hair Serum -- 1.76 ozBabe OriginalBeauty & Personal Carecaprylyl glycol, butylene glycol, apigenin, arginine, benzoic acid, benzyl alcohol, gluconolactone, biotin, caffeine, tocopherol, dimethyl sulfone, disodium edta, tocopherol, glycerin, glycine, lactic acid, trisodium ethylenediamine disuccinate, oleanolic acid, phenoxyethanol, phenethyl alcohol, propanediol, sodium benzoate, sodium metabisulfite, sorbic acid, xylitol, zinc chloride2024-11-29 10:47:42
Babo Botanicals Daily Sheer Sunscreen SPF 40 Extra Sensitive For Face -- 1.7 fl ozBabo BotanicalsBeauty & Personal Carehydroxyethyl acrylate, and, ethylhexylglycerin, glycerin, triethoxycaprylylsilane, phenethyl alcohol2024-11-29 10:47:42
Babo Botanicals Smoothing Detangling Conditioner Spray Berry & Primrose -- 8 fl ozBabo BotanicalsBeauty & Personal Careisopropyl alcohol, cetearyl alcohol, tocopherol, ethylhexylglycerin, tocopherol, vitamin e, glycerin, phenethyl alcohol2024-11-29 10:47:42
Clearly Natural Essentials Glycerin Liquid Hand Soap with Vitamin E -- 12 fl ozClearly NaturalHousehold Essentialstocopherol acetate, vitamin E, vitamin E, glycerine, glycine, oleic acid, phenylethyl alcohol, potassium hydroxide2024-11-29 10:47:42
Honeybee Gardens Bellissima Volumizing Mascara - Coffee Bean -- 0.13 ozHoneybee GardensBeauty & Personal Careaminomethyl propanediol, cellulose, cetearyl alcohol, tocopherol, ethylhexylglycerin, tocopherol, hydroxyethylcellulose, phenethyl alcohol, propanediol, stearic acid, undecyl alcohol2024-11-29 10:47:42
Honeybee Gardens Pressed Mineral Powder Foundation Luminous -- 0.26 ozHoneybee GardensBeauty & Personal Caretocopherol, ethylhexylglycerin, tocopherol, phenethyl alcohol2024-11-29 10:47:42
Honeybee Gardens Truly Natural Lipstick Heirloom -- 0.13 ozHoneybee GardensBeauty & Personal Carephenethyl alcohol, propanediol, titanium dioxide, undecyl alcohol2024-11-29 10:47:42
Honeybee Gardens Truly Natural Lipstick San Francisco -- 0.13 ozHoneybee GardensBeauty & Personal CarePhenethyl Alcohol, Propanediol, Titanium Dioxide, Undecyl Alcohol2024-11-29 10:47:42
Jason Body Wash Pure Relaxing Chamomile & Lotus Blossom -- 30 fl ozJasonBeauty & Personal Carecitric acid, allantoin, terpineol, benzyl alcohol, citric acid, panthenol, triethyl citrate, glycerin, phenethyl alcohol, sodium benzoate, stearic acid2024-11-29 10:47:42
Jason Dandruff Relief 2 in1 Shampoo + Conditioner -- 12 fl ozJasonBeauty & Personal Careglyceryl oleate, orange, citric acid, terpineol, benzylacetate, cetyl alcohol, citric acid, triethyl citrate, glycerin, limonene, linalool, maltodextrin, phenethyl alcohol, sodium cocoyl glutamate, sodium hydroxide, zinc carbonate2024-11-29 10:47:42
Jason Extra Volumizing Biotin Conditioner -- 8 fl ozJasonBeauty & Personal Careisopropyl alcohol, citric acid, ascorbyl palmitate, linolenic acid, benzyl alcohol, biotin, cetearyl alcohol, cetyl alcohol, citric acid, panthenol, triethyl citrate, glycerin, linoleic acid, maltodextrin, menthol, phenoxyethanol, phenethyl alcohol, stearyl alcohol2024-11-29 10:47:42
Jason Intense Moisture Conditioner Aloe Vera + Prickly Pear -- 16 fl ozJasonBeauty & Personal Careisopropyl alcohol, phytantriol, citric acid, ascorbyl palmitate, linolenic acid, terpineol, benzyl alcohol, betaine, cetearyl alcohol, cetyl alcohol, citric acid, panthenol, triethyl citrate, glycerin, linoleic acid, phenoxyethanol, phenethyl alcohol, stearyl alcohol2024-11-29 10:47:42
Jason Purifying Tea Tree Conditioner -- 12 fl ozJasonBeauty & Personal Careisopropyl alcohol, citric acid, linolenic acid, terpineol, benzyl alcohol, cetearyl alcohol, cetyl alcohol, citric acid, tocopherol, panthenol, triethyl citrate, tocopherol, glycerin, linoleic acid, phenethyl alcohol, stearyl alcohol2024-11-29 10:47:42
Jason Shampoo Jojoba plus Castor Oil Strong & Healthy -- 16 fl ozJasonBeauty & Personal Carecitric acid, terpineol, benzyl alcohol, citric acid, panthenol, triethyl citrate, glycerin, maltodextrin, phenoxyethanol, phenethyl alcohol2024-11-29 10:47:42
Jason Thicken & Restore Biotin + Hyaluronic Acid Shampoo -- 16 fl ozJasonBeauty & Personal Carecitric acid, ascorbyl palmitate, benzyl alcohol, biotin, citric acid, panthenol, triethyl citrate, glycerin, linoleic acid, menthol, phenoxyethanol, phenethyl alcohol2024-11-29 10:47:42
Mad Hippie Blemish Cream -- 0.5 fl ozMad HippieBeauty & Personal Carecaprylyl glycol, glyceryl oleate, astaxanthin, cetyl alcohol, curcumin, ethylhexyl glycerin, fucoxanthin, glyceryl stearate, glycerin, microcrystalline cellulose, isopropyl palmitate, phenethyl alcohol, squalane, stearyl alcohol2024-11-29 10:47:42
Mad Hippie Corrective Peptide Serum -- 1.02 fl ozMad HippieBeauty & Personal Carecaprylyl glycol, orange, ceramide NP, ethylhexyl glycerin, glycerin, hydroxyethylcellulose, oat, phenethyl alcohol, propanediol, squalane, stearyl alcohol2024-11-29 10:47:42
Mad Hippie Day-Night Vitamin C and Super A Serum Dual Pack -- 0.5 fl ozMad HippieBeauty & Personal Carecaprylyl glycol, dimethyl isosorbide, acetyl glucosamine, vitamin c, vitamin e, ethylhexyl glycerin, ferulic acid, vitamin e, glycerin, phenethyl alcohol, stearyl alcohol, tocotrienol2024-11-29 10:47:42
Mad Hippie Face Cream -- 1 fl ozMad HippieBeauty & Personal Carecaprylyl glycol, citric acid, cetearyl alcohol, citric acid, tocopherol, ethylhexylglycerin, tocopherol, glyceryl stearate, glycerin, isopropyl palmitate, phenethyl alcohol, sorbic acid, tocotrienol, ubiquinone2024-11-29 10:47:42
Mad Hippie Holiday Skin Care Gift Bag -- 1 SetMad HippieBeauty & Personal Carecaprylyl glycol, orange, allantoin, ascorbyl glucoside, vitamin C, ceramide 3, cetyl alcohol, vitamin E, and, ethylhexyl glycerin, ferulic acid, vitamin E, glyceryl stearate, glycerin, hydroxyethylcellulose, isopropyl palmitate, oat, phenethyl alcohol, propanediol, vitamin B2, squalane, stearic acid, stearyl alcohol, tocotrienol2024-11-29 10:47:42
Mad Hippie Jelly Cleanser -- 4 fl ozMad HippieBeauty & Personal Carecaprylyl glycol, chamomile, tocopherol, decyl glucoside, ethylhexyl glycerin, tocopherol, phenethyl alcohol, resveratrol2024-11-29 10:47:42
Mad Hippie Microdermabrasion Facial -- 2.1 ozMad HippieBeauty & Personal Carecaprylyl glycol, orange, cetyl alcohol, ethylhexyl glycerin, glycerin, glycolic acid, lactic acid, mandelic acid, probiotic, myristic acid, phenethyl alcohol, squalane, stearic acid2024-11-29 10:47:42
Mad Hippie Super Vitamin A Serum -- 1.02 fl ozMad HippieBeauty & Personal Carecaprylyl glycol, dimethyl isosorbide, acetyl glucosamine, ethylhexyl glycerin, glycerin, phenethyl alcohol, stearyl alcohol2024-11-29 10:47:42
Mad Hippie Triple C Night Cream -- 2.1 ozMad HippieBeauty & Personal Carecaprylyl glycol, allantoin, ascorbyl glucoside, vitamin C, ceramide 3, cetyl alcohol, vitamin E, and, ethylhexyl glycerin, vitamin E, glyceryl stearate, glycerin, isopropyl palmitate, phenethyl alcohol, vitamin B2, squalane, stearic acid, tocotrienol2024-11-29 10:47:42
Mad Hippie Vitamin C Toning Mist -- 4 fl ozMad HippieBeauty & Personal Carecaprylyl glycol, N-acetyl glucosamine, ethylhexyl glycerin, ferulic acid, glycerin, phenethyl alcohol2024-11-29 10:47:42
Mineral Fusion Lipstick Cosmopolitan -- 0.13 ozMineral FusionBeauty & Personal Caretocopherol, tocopherol, phenethyl alcohol, titanium dioxide2024-11-29 10:47:42
Mineral Fusion Lipstick Paloma -- 0.13 ozMineral FusionBeauty & Personal Caretocopherol, tocopherol, phenethyl alcohol, titanium dioxide2024-11-29 10:47:42
Mineral Fusion Lipstick Passion Punch -- 0.13 ozMineral FusionBeauty & Personal Caretocopherol, tocopherol, phenethyl alcohol, titanium dioxide2024-11-29 10:47:42
Mineral Fusion Lipstick Peach Bellini -- 0.13 ozMineral FusionBeauty & Personal Caretocopherol, tocopherol, phenethyl alcohol, titanium dioxide2024-11-29 10:47:42
Mineral Fusion Lipstick Plum Prosecco -- 0.13 ozMineral FusionBeauty & Personal Caretocopherol, tocopherol, phenethyl alcohol, titanium dioxide2024-11-29 10:47:42
Mineral Fusion Lipstick Plum Wine -- 0.13 ozMineral FusionBeauty & Personal Caretocopherol, tocopherol, phenethyl alcohol, titanium dioxide2024-11-29 10:47:42
Mineral Fusion Lipstick Rose Sangria -- 0.13 ozMineral FusionBeauty & Personal Caretocopherol, tocopherol, phenethyl alcohol, titanium dioxide2024-11-29 10:47:42
MyChelle Dermaceuticals Ageless Supreme Polypeptide Cream Unscented -- 1.2 fl ozMyChelle DermaceuticalsBeauty & Personal CareD-Alpha, Caprylyl Glycol, Orange, Citric Acid, Cetearyl Alcohol, Palm, Citric Acid, Tocopherol, Tocopherol, Glycerin, Trisodium Ethylenediamine Disuccinate, Phenethyl Alcohol, Squalane, Tocotrienols, Totarol2024-11-29 10:47:42
MyChelle Dermaceuticals Brighten Perfect C Eye Cream -- 0.5 fl ozMyChelle DermaceuticalsBeauty & Personal CareD-alpha, caprylyl glycol, orange, citric acid, allantoin, ascorbic acid, cetearyl alcohol, cetyl alcohol, palm, citric acid, tocopherol, tocopherol, palmarosa, sodium gluconate, glyceryl stearate, glycerin, phenethyl alcohol, phytic acid, stearic acid, tocotrienols2024-11-29 10:47:42
MyChelle Dermaceuticals Hydrate Ultra Hyaluronic Hydrating Serum -- 1 fl ozMyChelle DermaceuticalsBeauty & Personal Carecaprylyl glycol, geranium, citric acid, allantoin, arginine, D-beta, citric acid, glycerin, trisodium ethylenediamine disuccinate, phenethyl alcohol, squalane2024-11-29 10:47:42
MyChelle Dermaceuticals Renew Remarkable Retinal Night Cream -- 1.2 fl ozMyChelle DermaceuticalsBeauty & Personal CareD-alpha, caprylyl glycol, citric acid, allantoin, ascorbic acid, D-beta, carnosine, casticin, cetearyl alcohol, palm, citric acid, tocopherol, tocopherol, glyceryl stearate, glycerin, trisodium ethylenediamine disuccinate, phenethyl alcohol, retinaldehyde, squalane, stearic acid, tocotrienols, totarol, trehalose2024-11-29 10:47:42
MyChelle Dermaceuticals Strengthen Creamy Pumpkin Cleanser -- 4.4 fl ozMyChelle DermaceuticalsBeauty & Personal Carecaprylyl glycol, astaxanthin, behenyl alcohol, glycerin, trisodium ethylenediamine disuccinate, phenethyl alcohol, nutmeg, sugar2024-11-29 10:47:42
MyChelle Dermaceuticals Strengthen Fruit Enzyme Scrub -- 2.3 fl ozMyChelle DermaceuticalsBeauty & Personal Carecaprylyl glycol, calendula, panthenol, behenyl alcohol, glycerin, trisodium ethylenediamine disuccinate, phenethyl alcohol, sodium cocoyl glutamate2024-11-29 10:47:42
MyChelle Dermaceuticals Strengthen Pumpkin Renew Cream -- 1.2 fl ozMyChelle DermaceuticalsBeauty & Personal CareD-alpha, caprylyl glycol, orange, astaxanthin, gluconolactone, D-beta, carnosine, cetearyl alcohol, chlorophyll, palm, tocopherol, tocopherol, glyceryl stearate, glycerin, lactic acid, phenyl t-butylnitrone, phenethyl alcohol, nutmeg, sodium benzoate, tocotrienols, totarol2024-11-29 10:47:42
Sibu Beauty Hydrating Serum Sea Buckthorn -- 1 fl ozSibu BeautyBeauty & Personal Carebetaine, tocopherol, tocopherol, glycerin, phenethyl alcohol, retinyl palmitate2024-11-29 10:47:42
The Seaweed Bath Co Calm Body Wash - Vetiver Geranium -- 12 fl ozThe Seaweed Bath CoBeauty & Personal Caregeranium, citric acid, citric acid, cocamidopropyl betaine, decyl glucoside, ethylhexylglycerin, glycerin, phenethyl alcohol2024-11-29 10:47:42
The Seaweed Bath Co Detox Body Scrub - Orange Cedar -- 6 fl ozThe Seaweed Bath CoBeauty & Personal Carecarbomer, cocamidopropyl betaine, ethylhexylglycerin, phenethyl alcohol, montmorillonite2024-11-29 10:47:42
The Seaweed Bath Co Detox Body Scrub - Rosemary Mint -- 1.5 fl ozThe Seaweed Bath CoBeauty & Personal Carecocamidopropyl betaine, vitamin e, triethyl citrate, ethylhexylglycerin, vitamin e, glycerin, illite, kaolin, phenethyl alcohol, montmorillonite, sodium hydroxide2024-11-29 10:47:42
The Seaweed Bath Co Detox Body Scrub - Rosemary Mint -- 6 fl ozThe Seaweed Bath CoBeauty & Personal Carecarbomer, cocamidopropyl betaine, ethylhexylglycerin, phenethyl alcohol, montmorillonite2024-11-29 10:47:42
The Seaweed Bath Co Energize Body Wash - Grapefruit Orange -- 12 fl ozThe Seaweed Bath CoBeauty & Personal Careorange, ascorbic acid, cocamidopropyl betaine, decyl glucoside, ethylhexylglycerin, glycerin, phenethyl alcohol2024-11-29 10:47:42
The Seaweed Bath Co Firming Body Cream - Rosemary Mint -- 6 fl ozThe Seaweed Bath CoBeauty & Personal Careallantoin, caffeine, carbomer, tocopherol, panthenol, ethylhexylglycerin, tocopherol, glyceryl stearate, phenethyl alcohol, stearic acid, stearyl alcohol2024-11-29 10:47:42
The Seaweed Bath Co Hydrate Body Cream - Citrus Vanilla -- 6 fl ozThe Seaweed Bath CoBeauty & Personal Careorange, allantoin, tocopherol, panthenol, methyl sulfonyl methane, tocopherol, glyceryl stearate, phenethyl alcohol, stearic acid, stearyl alcohol, vanilla2024-11-29 10:47:42
The Seaweed Bath Co Hydrate Body Cream - Lavender -- 6 fl ozThe Seaweed Bath CoBeauty & Personal Careallantoin, tocopherol, panthenol, methyl sulfonyl methane, tocopherol, glyceryl stearate, phenethyl alcohol, stearic acid, stearyl alcohol2024-11-29 10:47:42
The Seaweed Bath Co Hydrate Body Cream - Unscented -- 6 fl ozThe Seaweed Bath CoBeauty & Personal Caretocopherol, panthenol, methyl sulfonyl methane, tocopherol, glyceryl stearate, phenethyl alcohol, stearic acid, stearyl alcohol2024-11-29 10:47:42

Roles (5)

RoleDescription
fragranceA substance, extract, or preparation for diffusing or imparting an agreeable or attractive smell.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
Aspergillus metaboliteAny fungal metabolite produced during a metabolic reaction in the mould, Aspergillus.
plant growth retardantnull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (8)

PathwayProteinsCompounds
tea aroma glycosidic precursor bioactivation110
L-phenylalanine degradation III112
phenylethanol glycoconjugate biosynthesis06
phenylethyl acetate biosynthesis14
phenylethanol biosynthesis914
tea aroma glycosidic precursor bioactivation116
phenylethanol glycoconjugate biosynthesis07
L-phenylalanine degradation III1213
phenylethanol biosynthesis815
phenylalanine degradation1112
phenylalanine degradation III112
Ehrlich pathway011

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency100.00000.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency89.12510.004023.8416100.0000AID485290
RAR-related orphan receptor gammaMus musculus (house mouse)Potency20.24780.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency59.50830.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency22.61420.000221.22318,912.5098AID743036; AID743053
progesterone receptorHomo sapiens (human)Potency33.49150.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency10.96400.01237.983543.2770AID1645841
farnesoid X nuclear receptorHomo sapiens (human)Potency16.78420.375827.485161.6524AID743239
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.09820.000229.305416,493.5996AID743069
cytochrome P450 2D6Homo sapiens (human)Potency24.54540.00108.379861.1304AID1645840
gemininHomo sapiens (human)Potency0.56230.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (51)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1090484Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth at 500 ug/mL measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID1101945Inhibition of intact Triticum aestivum (wheat) seed germination assessed as appearance of distinct rootlets at 500 ppm after 4 days relative to wheat grains RL4137 germination2002Journal of agricultural and food chemistry, Oct-23, Volume: 50, Issue:22
Germination and growth inhibitors from wheat (Triticum aestivum L.) husks.
AID1101944Inhibition of intact Triticum aestivum (wheat) seed germination assessed as appearance of sprouts at 500 ppm after 4 days relative to wheat grains RL4137 germination2002Journal of agricultural and food chemistry, Oct-23, Volume: 50, Issue:22
Germination and growth inhibitors from wheat (Triticum aestivum L.) husks.
AID1101946Growth inhibition of intact Triticum aestivum (wheat) seed assessed as appearance of sprouts at 500 ppm after 4 days relative to wheat grains RL4137 germination2002Journal of agricultural and food chemistry, Oct-23, Volume: 50, Issue:22
Germination and growth inhibitors from wheat (Triticum aestivum L.) husks.
AID1090481Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth at 2000 ug/mL measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID1090713Thrips luring activity against female New Zealand Thrips obscuratus (flower thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study2007Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15
4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1101947Growth inhibition of intact Triticum aestivum (wheat) seed assessed as appearance of distinct rootlets at 500 ppm after 4 days relative to wheat grains RL4137 germination2002Journal of agricultural and food chemistry, Oct-23, Volume: 50, Issue:22
Germination and growth inhibitors from wheat (Triticum aestivum L.) husks.
AID1090712Thrips luring activity against male New Zealand Thrips obscuratus (flower thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study2007Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15
4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments.
AID1090482Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth at 1500 ug/mL measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID1102450Fungitoxicity against Colletotrichum gloeosporioides assessed as mycelial growth inhibition by poisoned food technique2003Journal of agricultural and food chemistry, Aug-27, Volume: 51, Issue:18
Quantitative structure-fungitoxicity relationships of some monohydric alcohols.
AID1090711Thrips luring activity against female Thrips tabaci (onion thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study2007Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15
4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments.
AID1090483Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth at 1000 ug/mL measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID1090485Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth at 100 ug/mL measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID762933Antimelanogenic activity in mouse B16F10 cells assessed as inhibition of alpha-MSH-induced melanin production at 1 to 2 uM after 72 hrs by spectrophotometry2013Journal of natural products, Aug-23, Volume: 76, Issue:8
Caffeic acid phenethyl ester inhibits alpha-melanocyte stimulating hormone-induced melanin synthesis through suppressing transactivation activity of microphthalmia-associated transcription factor.
AID1090480Antifungal activity against Colletotrichum camelliae assessed as inhibition of mycelial growth measured after 5 days of cultivation2006Journal of agricultural and food chemistry, May-31, Volume: 54, Issue:11
Antifungal activities of major tea leaf volatile constituents toward Colletorichum camelliae Massea.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,607)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990137 (5.26)18.7374
1990's109 (4.18)18.2507
2000's662 (25.39)29.6817
2010's1288 (49.41)24.3611
2020's411 (15.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 63.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index63.70 (24.57)
Research Supply Index7.92 (2.92)
Research Growth Index5.22 (4.65)
Search Engine Demand Index111.29 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (63.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials63 (2.34%)5.53%
Reviews123 (4.56%)6.00%
Case Studies2 (0.07%)4.05%
Observational4 (0.15%)0.25%
Other2,504 (92.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Open Label Pilot Study Using Hydroxytyrosol (HT) as a Dietary Supplement in Patients With Mitochondrial Diseases (MDs) [NCT04543968]12 participants (Anticipated)Interventional2022-07-05Recruiting
Foods Such as Virgin Olive Oil Rich in Phenolic Compounds, and Prebiotic Supplementation: Dietary Strategy to Tackle Sarcopenia in Early Elderly Subjects (FOOP-Sarc) [NCT05485402]135 participants (Anticipated)Interventional2022-09-01Recruiting
The Effect of Suggestion of Harmful/Beneficial Effects of Odors on Asthma Symptoms [NCT02624362]48 participants (Anticipated)Interventional2015-08-31Enrolling by invitation
Effects of Punicalagin and Hydroxytyrosol Mixture on Different Inflammatory Markers Related With Cardiovascular Disease: a Crossover Study in Healthy Middle-aged Volunteers [NCT02042742]Phase 476 participants (Actual)Interventional2013-04-30Completed
Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment [NCT01155661]Phase 3608 participants (Actual)Interventional2010-10-31Completed
Hydroxytyrosol and Vitamin E in the Treatment of Children With Biopsy-proven NASH [NCT02842567]Phase 380 participants (Actual)Interventional2017-04-01Completed
Effect of LY2216684 on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Albuterol or Propranolol [NCT01263197]Phase 148 participants (Actual)Interventional2010-12-31Completed
A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction of LY2216684 With Alcohol in Healthy Subjects [NCT01380691]Phase 128 participants (Actual)Interventional2011-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01155661 (22) [back to overview]Change From Baseline to 54 Week Endpoint in Clinical Global Impression - Severity (CGI-S)
NCT01155661 (22) [back to overview]Change From Baseline to 54 Week Endpoint in EuroQol Questionnaire - 5 Dimension (EQ-5D)
NCT01155661 (22) [back to overview]Change From Baseline to 54 Week Endpoint in Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score
NCT01155661 (22) [back to overview]Change From Baseline to 54 Week Endpoint in Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score
NCT01155661 (22) [back to overview]Change From Baseline to 54 Week Endpoint in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)
NCT01155661 (22) [back to overview]Change From Baseline to 54 Week Endpoint in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)
NCT01155661 (22) [back to overview]Change From Baseline to 54 Week Endpoint in the Arizona Sexual Experiences (ASEX) Scale
NCT01155661 (22) [back to overview]Change From Baseline to Week 54 Endpoint in Pulse Rate
NCT01155661 (22) [back to overview]Percentage of Participants Who Meet Remission Criteria of Depressive Symptoms by Week 8
NCT01155661 (22) [back to overview]Percentage of Participants Who Meet Response Criteria of Depressive Symptoms by Week 8
NCT01155661 (22) [back to overview]Percentage of Participants With Discontinuation-Emergent Adverse Events (DEAEs)
NCT01155661 (22) [back to overview]Probability of Meeting the Remission Criteria for Depressive Symptoms at Week 54 Endpoint
NCT01155661 (22) [back to overview]Probability of Meeting the Response Criteria for Depressive Symptoms at Week 54 Endpoint
NCT01155661 (22) [back to overview]The Number of Participants Experiencing Clinically Significant Effects
NCT01155661 (22) [back to overview]Change From Baseline to 54 Week Endpoint in Blood Pressure
NCT01155661 (22) [back to overview]Change From Baseline to 54 Week Endpoint in Fatigue Associated With Depression (FAsD) Average Score and Subscale Scores
NCT01155661 (22) [back to overview]Change From Baseline to 54 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Items
NCT01155661 (22) [back to overview]Change From Baseline to 54 Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscores
NCT01155661 (22) [back to overview]Percent of Participants With Suicidal Ideation and Behavior Based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT01155661 (22) [back to overview]Percentage of Participants Who Reported Resource Utilization (RU) at Baseline and at the Week 54 Endpoint
NCT01155661 (22) [back to overview]Plasma Concentration of LY2216684
NCT01155661 (22) [back to overview]The Number of Participants Experiencing Clinically Significant Effects as a Function of CYP2D6 Predicted Phenotype at Week 54 Endpoint
NCT01263197 (3) [back to overview]Maximum, Minimum and Average Changes in Diastolic Blood Pressure
NCT01263197 (3) [back to overview]Maximum, Minimum and Average Changes in Heart Rate
NCT01263197 (3) [back to overview]Maximum, Minimum and Average Changes in Systolic Blood Pressure
NCT01380691 (14) [back to overview]Change From Baseline to 10 Hours in Continuity of Attention Composite Score
NCT01380691 (14) [back to overview]Change From Baseline to 10 Hours in Postural Stability
NCT01380691 (14) [back to overview]Change From Baseline to 10 Hours in Power of Attention Composite Score
NCT01380691 (14) [back to overview]Change From Baseline to 10 Hours in Self-Rated Alertness
NCT01380691 (14) [back to overview]Pharmacokinetics: Area Under the Concentration Time Curve From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Alcohol
NCT01380691 (14) [back to overview]Pharmacokinetics: Area Under the Concentration Time Curve Over a Dosing Interval (AUCt) of LY2216684
NCT01380691 (14) [back to overview]Pharmacokinetics: Observed Cmax of Alcohol
NCT01380691 (14) [back to overview]Pharmacokinetics: Observed Maximum Plasma Concentration (Cmax) of LY2216684
NCT01380691 (14) [back to overview]Pharmacokinetics: Observed Time to Maximum Plasma Concentration (Tmax) of LY2216684
NCT01380691 (14) [back to overview]Pharmacokinetics: Observed Tmax of Alcohol
NCT01380691 (14) [back to overview]Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Episodic Memory
NCT01380691 (14) [back to overview]Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Self-Ratings of Calmness and Contentment
NCT01380691 (14) [back to overview]Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Speed of Retrieval of Information From Memory
NCT01380691 (14) [back to overview]Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Working Memory

Change From Baseline to 54 Week Endpoint in Clinical Global Impression - Severity (CGI-S)

Clinical Global Impression - Severity (CGI-S) measures severity of depression at the time of assessment compared with the start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline score, and baseline-by-visit. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionunits on a scale (Least Squares Mean)
LY2216684 + SSRI-2.17

[back to top]

Change From Baseline to 54 Week Endpoint in EuroQol Questionnaire - 5 Dimension (EQ-5D)

The EQ-5D Visual Analog Scale is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score is self-reported using a visual analogue scale, marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline score, and baseline-by-visit. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionunits on a scale (Least Squares Mean)
LY2216684 + SSRI23.607

[back to top]

Change From Baseline to 54 Week Endpoint in Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score

The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscale. Scores of 11 or more on either subscale were considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.' Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline score, and baseline-by-visit. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionunits on a scale (Least Squares Mean)
LY2216684 + SSRI-4.57

[back to top]

Change From Baseline to 54 Week Endpoint in Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score

The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item is rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscales. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.' Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline score, and baseline-by-visit. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionunits on a scale (Least Squares Mean)
LY2216684 + SSRI-6.32

[back to top]

Change From Baseline to 54 Week Endpoint in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)

The CPFQ is a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assesses motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent). Total scores ranged from 7 to 42. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline score, and baseline-by-visit. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionunits on a scale (Least Squares Mean)
LY2216684 + SSRI-8.64

[back to top]

Change From Baseline to 54 Week Endpoint in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)

The Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) is a self-administered 16 item questionnaire measuring degree of enjoyment and satisfaction experienced in various areas of daily life during the past week on a 5-point Likert scale (1=very poor and 5=very good). The total raw score is the sum of Items 1 to 14 and ranges from 14 to 70. The raw scores are converted to and expressed as the percentage of the maximum possible score. Higher scores indicate higher levels of enjoyment/satisfaction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline score, and baseline-by-visit. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionunits on a scale (Least Squares Mean)
LY2216684 + SSRI21.56

[back to top]

Change From Baseline to 54 Week Endpoint in the Arizona Sexual Experiences (ASEX) Scale

The ASEX scale was used to assess sexual functioning in both males and females. The ASEX total score for the male and female version was calculated as the sum of the responses (rated from 1 [extremely] to 6 [no/never]) to the 5 items of the ASEX scale. Total scores ranged from 5 to 30 with higher scores indicating greater sexual dysfunction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline score, and baseline-by-visit. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionunits on a scale (Least Squares Mean)
LY2216684 + SSRI-2.28

[back to top]

Change From Baseline to Week 54 Endpoint in Pulse Rate

Pulse measurements were collected when the participant was in a sitting position. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline value, and baseline-by-visit. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionbeats per minute (bpm) (Least Squares Mean)
LY2216684 + SSRI7.01

[back to top]

Percentage of Participants Who Meet Remission Criteria of Depressive Symptoms by Week 8

Remission criteria was defined as a Montgomery-Asberg Depression Rating Scale (MADRS) total score of <= 10. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). The Kaplan-Meier product limit method of time to first remission was calculated. In the calculation, participants who did not meet remission criteria were considered as right-censored observations. The estimated percentage of participants who meet remission criteria by Week 8 from the Kaplan-Meier method is presented. (NCT01155661)
Timeframe: Baseline, Week 8

Interventionpercentage of participants (Number)
LY2216684 + SSRI47.7

[back to top]

Percentage of Participants Who Meet Response Criteria of Depressive Symptoms by Week 8

Response criteria was defined as at least a 50% decrease from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). The Kaplan-Meier product limit method of time to first response was calculated. In the calculation, participants who did not meet response criteria were considered as right-censored observations. The estimated percentage of participants who met response criteria by Week 8 from the Kaplan-Meier method is presented. (NCT01155661)
Timeframe: Baseline, Week 8

Interventionpercentage of participants (Number)
LY2216684 + SSRI59.2

[back to top]

Percentage of Participants With Discontinuation-Emergent Adverse Events (DEAEs)

Discontinuation-emergent adverse events (DEAEs) were events that first occurred or worsened within 1-week after abrupt discontinuation of LY2216684 (edivoxetine) treatment. (NCT01155661)
Timeframe: Up to1 week after discontinuation of treatment

Interventionpercentage of participants (Number)
LY2216684 + SSRI20.97

[back to top]

Probability of Meeting the Remission Criteria for Depressive Symptoms at Week 54 Endpoint

Remission criteria was defined as a Montgomery-Asberg Depression Rating Scale (MADRS) total score of <= 10. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). This analysis models the probability of remission at each visit, and the estimated probabilities were adjusted for visit and the baseline MADRS total score. (NCT01155661)
Timeframe: Baseline, Week 54

InterventionProbability of remission (Number)
LY2216684 + SSRI0.758

[back to top]

Probability of Meeting the Response Criteria for Depressive Symptoms at Week 54 Endpoint

Response criteria was defined as at least a 50% decrease from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). This analysis models the probability of response at each visit, and the estimated probabilities were adjusted for visit and the baseline MADRS total score. (NCT01155661)
Timeframe: Baseline, Week 54

InterventionProbability of response (Number)
LY2216684 + SSRI0.772

[back to top]

The Number of Participants Experiencing Clinically Significant Effects

"A clinically significant effect was defined as a serious adverse event, regardless of causality.~A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Event module." (NCT01155661)
Timeframe: Baseline through 54 weeks

Interventionparticipants (Number)
LY2216684 + SSRI13

[back to top]

Change From Baseline to 54 Week Endpoint in Blood Pressure

Blood pressure measurements were collected when the participant was in a sitting position. Three measurements of sitting blood pressure collected at approximately 1-minute intervals at every visit were averaged and used as the value for the visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline value, and baseline-by-visit. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionmillimeters of mercury (mm Hg) (Least Squares Mean)
Sitting Systolic Blood PressureSitting Diastolic Blood Pressure
LY2216684 + SSRI2.282.17

[back to top]

Change From Baseline to 54 Week Endpoint in Fatigue Associated With Depression (FAsD) Average Score and Subscale Scores

"The Fatigue Associated with Depression (FAsD) is a participant-rated scale with a total of 13 items. Six of the 13 items ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Seven of the 13 items ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The Experience Score was derived by taking the mean of Items 1 through 6, the Impact Score was derived by taking the mean of Items 7 through 13 (applicable items only), and the Average Score was the mean of Items 1 through 13 (derived by taking the mean of all applicable items for each participant). Item 12 applied only to participants with a spouse or significant other and Item 13 applied to participants who had a job or who went to school. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline score, and baseline-by-visit." (NCT01155661)
Timeframe: Baseline, Week 54

Interventionunits on a scale (Least Squares Mean)
FAsD Experience ScoreFAsD Impact ScoreFAsD Average Score
LY2216684 + SSRI-1.25-1.37-1.30

[back to top]

Change From Baseline to 54 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Items

The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline score, and baseline-by-visit. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionunits on a scale (Least Squares Mean)
MADRS Item 1: Apparent SadnessMADRS Item 2: Reported SadnessMADRS Item 3: Inner TensionMADRS Item 4: Reduced SleepMADRS Item 5: Reduced AppetiteMADRS Item 6: Concentration DifficultiesMADRS Item 7: LassitudeMADRS Item 8: Inability to FeelMADRS Item 9: Pessimistic ThoughtsMADRS Item 10: Suicidal ThoughtsMADRS Total Score
LY2216684 + SSRI-2.17-2.38-1.56-1.97-1.08-1.88-2.18-2.22-1.52-0.26-16.97

[back to top]

Change From Baseline to 54 Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscores

The Sheehan Disability Scale (SDS) Global Functional Impairment Score (total score) and Subscores were completed by the participant and were used to assess the effect of the participant's symptoms on their work (Item 1), social (Item 2), and family life (Item 3). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. The Global Functional Impairment Score is the sum of the 3 items, and scores ranged from 0 to 30 with higher values indicating greater disruption in the participant's work life (work/school impairment [imp] score), social life (social life/leisure activities impairment [imp] score), and family life (family life/home responsibilities impairment [imp] score). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for investigator, visit, baseline score, and baseline-by-visit. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionunits on a scale (Least Squares Mean)
SDS Global Functional Impairment(Imp) ScoreWork/School Imp ScoreSocial Life/Leisure Activity Imp ScoreFamily Life/Home Responsibility Imp Score
LY2216684 + SSRI-10.71-3.36-3.74-3.61

[back to top]

Percent of Participants With Suicidal Ideation and Behavior Based on the Columbia-Suicide Severity Rating Scale (C-SSRS)

"The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation was defined as a yes answer to any 1 of 5 suicidal ideation questions, which included a wish to be dead and 4 different categories of active suicidal ideation. Suicidal behavior was defined as a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide." (NCT01155661)
Timeframe: Baseline through Week 54

Interventionpercentage of participants (Number)
Suicidal IdeationSuicidal Behavior
LY2216684 + SSRI11.710.17

[back to top]

Percentage of Participants Who Reported Resource Utilization (RU) at Baseline and at the Week 54 Endpoint

The Resource Utilization (RU) form assesses the frequency and type of medical services (a primary care visit and/or a psychiatrist visit) that participants used within the previous year (for the baseline visit) or within approximately the previous 3 months (for post-baseline visits or the Week 54 endpoint). The percentage of participants who reported greater than zero number of primary care doctor visits and greater than zero number of psychiatrist visits is presented. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionpercentage of participants (Number)
Primary Care Doctor Visits, BaselinePrimary Care Doctor Visits, Week 54Psychiatrist Visits, BaselinePsychiatrist Visits, Week 54
LY2216684 + SSRI62.2730.1844.154.75

[back to top]

Plasma Concentration of LY2216684

(NCT01155661)
Timeframe: Weeks 2, 6, and 8

Interventionnanograms per milliliter (ng/mL) (Mean)
12 mg dose18 mg dose
LY2216684 + SSRI29.653.6

[back to top]

The Number of Participants Experiencing Clinically Significant Effects as a Function of CYP2D6 Predicted Phenotype at Week 54 Endpoint

A clinically significant effect was defined as a treatment-emergent adverse event; a reported adverse event that first occurred or worsened during the treatment phase. CYP2D6 predicted phenotype was classified as poor metabolizer (PM) or non-poor metabolizer (non-PM). The number of participants who reported at least one treatment-emergent adverse event is presented for each phenotype classification. (NCT01155661)
Timeframe: Baseline, Week 54

Interventionparticipants (Number)
Poor MetabolizerNon-poor Metabolizer
LY2216684 + SSRI17408

[back to top]

Maximum, Minimum and Average Changes in Diastolic Blood Pressure

Diastolic blood pressure was measured using ambulatory blood pressure monitoring (ABPM) recorded every 15 minutes during the daytime (0600 through 2200 hours) and every hour throughout the night time (2200 through 0600 hours) on Days 1, 3, and 5 of each period. Baseline diastolic blood pressure was the average of 15-minute readings taken over 2 hours prior to dosing on Day 1 of each period. Postdose diastolic blood pressure from ABPM was summarized over 1-hour increments using the average of the 15-minute readings within these intervals. The postdose diastolic blood pressure for a day was the average diastolic blood pressure for 24 hours. The least squares (LS) mean change from baseline diastolic blood pressure is reported. LS mean was calculated using a mixed effects model and adjusted for participant, sequence, period, time, treatment, and time by treatment interaction. (NCT01263197)
Timeframe: Period 1, 2, 3: Baseline, Days 1 and 3 and 5 (postdose every 15 minutes from 0600 hours through 2200 hours and every hour from 2200 hours through 0600 hours)

,,,,,
Interventionmillimeters of mercury (mm Hg) (Least Squares Mean)
Day 1 Maximum ChangeDay 1 Minimum ChangeDay 1 Average ChangeDay 3 Maximum ChangeDay 3 Minimum ChangeDay 3 Average ChangeDay 5 Maximum ChangeDay 5 Minimum ChangeDay 5 Average
Albuterol10.8-19.9-3.2711.8-21.5-3.1012.8-21.6-3.17
LY2216684 (Group 1)13.4-17.3-0.67413.6-18.1-0.53713.8-17.00.233
LY2216684 (Group 2)14.9-17.90.48115.4-17.80.61913.1-19.1-0.631
LY2216684+Albuterol12.2-16.2-0.87312.7-18.6-0.15914.7-20.5-0.140
LY2216684+Propranolol10.6-17.6-1.4412.5-18.8-1.2013.8-21.0-1.80
Propranolol8.16-26.7-7.476.87-26.6-7.806.58-26.6-7.33

[back to top]

Maximum, Minimum and Average Changes in Heart Rate

Using a Holter monitor, heart rate was recorded every 10 minutes through 24 hours postdose on Days 1, 3, and 5 of each period. Baseline heart rate was the average of 10-minute readings taken over 2 hours prior to dosing on Day 1 of each period. Postdose heart rate was summarized over 1-hour increments using the average of the 10-minute readings within these intervals. The postdose heart rate for a day was the average heart rate for 24 hours. The least squares (LS) mean change from baseline heart rate is reported. LS mean was calculated using a mixed effects model and adjusted for participant, sequence, period, time, treatment, and time by treatment interaction. (NCT01263197)
Timeframe: Period 1, 2, 3: Baseline, Days 1 and 3 and 5 (postdose every 10 minutes through 24 hours postdose)

,,,,,
Interventionbeats per minute (bpm) (Least Squares Mean)
Day 1 Maximum ChangeDay 1 Minimum ChangeDay 1 Average ChangeDay 3 Maximum ChangeDay 3 Minimum ChangeDay 3 Average ChangeDay 5 Maximum ChangeDay 5 Minimum ChangeDay 5 Average Change
Albuterol15.7-15.2-0.78819.7-16.30.10219.9-16.31.05
LY2216684 (Group 1)33.4-9.239.3336.3-7.0512.640.4-9.4714.6
LY2216684 (Group 2)31.1-5.819.5537.2-5.9414.236.9-5.2115.0
LY2216684+Albuterol35.7-9.0310.937.2-9.7614.339.3-7.2715.7
LY2216684+Propranolol17.2-10.41.1127.3-9.406.0126.3-9.466.25
Propranolol9.41-14.8-3.9415.2-16.1-4.3414.0-15.4-3.65

[back to top]

Maximum, Minimum and Average Changes in Systolic Blood Pressure

Systolic blood pressure was measured using ambulatory blood pressure monitoring (ABPM) recorded every 15 minutes during the daytime (0600 through 2200 hours) and every hour throughout the night time (2200 through 0600 hours) on Days 1, 3, and 5 of each period. Baseline systolic blood pressure was the average of 15-minute readings taken over 2 hours prior to dosing on Day 1 of each period. Postdose systolic blood pressure from ABPM was summarized over 1-hour increments using the average of the 15-minute readings within these intervals. The postdose systolic blood pressure for a day was the average systolic blood pressure for 24 hours. The least squares (LS) mean change from baseline systolic blood pressure is reported. LS mean was calculated using a mixed effects model and adjusted for participant, sequence, period, time, treatment, and time by treatment interaction. (NCT01263197)
Timeframe: Period 1, 2, 3: Baseline, Days 1 and 3 and 5 (postdose every 15 minutes from 0600 hours through 2200 hours and every hour from 2200 hours through 0600 hours)

,,,,,
Interventionmillimeters of mercury (mm Hg) (Least Squares Mean)
Day 1 Maximum ChangeDay 1 Minimum ChangeDay 1 Average ChangeDay 3 Maximum ChangeDay 3 Minimum ChangeDay 3 Average ChangeDay 5 Maximum ChangeDay 5 Minimum ChangeDay 5 Average Change
Albuterol15.2-20.5-0.91215.6-24.9-1.8715.9-22.1-2.36
LY2216684 (Group 1)14.1-18.0-0.98613.5-19.4-1.6513.9-20.8-2.07
LY2216684 (Group 2)17.3-17.71.7315.3-18.50.28914.7-21.1-1.72
LY2216684+Albuterol15.8-15.31.6913.5-20.6-1.9916.2-18.9-0.233
LY2216684+Propranolol10.9-17.5-1.3511.2-23.3-3.9113.1-21.2-2.55
Propranolol9.39-29.0-8.507.99-27.2-8.7511.1-24.9-6.83

[back to top]

Change From Baseline to 10 Hours in Continuity of Attention Composite Score

"Continuity of attention is a measure of sustained attention, combining (summed) accuracy and error measures from the choice reaction time and digit vigilance tasks. The number of correct responses (out of 50) for choice reaction time was added to the total number of targets correctly identified (out of 45) digit vigilance minus the number of false alarms (total score of -45 to 95). A high score reflects someone able to keep his/her mind on a single task for a prolonged period. A negative change from baseline reflects impairment compared to baseline.~LS means were calculated using mixed model ANCOVA adjusting for predose, sequence, period, day, time, treatment, and treatment*time as fixed effects and participant within sequence and treatment as random effect." (NCT01380691)
Timeframe: Baseline, 10 hours

Interventionunits on a scale (Least Squares Mean)
LY2216684 + Alcohol-4.21
Placebo-matching LY2216684 + Alcohol-1.16
LY2216684 + Placebo-matching Alcohol-3.31
Placebo-matching LY2216684 + Placebo-matching Alcohol-1.24

[back to top]

Change From Baseline to 10 Hours in Postural Stability

"The ability to stand upright without moving was assessed using equipment modeled on the Wright Ataxia-meter. To measure movements, a cord was attached to the participant who was required to stand for one minute, as still as possible, with feet apart and eyes closed. The amount of sway is expressed as the total angular movement calibrated in units of one-third degree of angle of sway.~The amount of sway is expressed as the total angular movement in the antero-posterior plane and calibrated in units of one-third degree of angle of sway. Higher result indicates better postural stability. A negative change from baseline reflects impairment compared to baseline. LS means were calculated using mixed model ANCOVA adjusting for predose, sequence, period, day, time, treatment, and treatment*time as fixed effects and participant within sequence and treatment as random effect." (NCT01380691)
Timeframe: Baseline, 10 hours

Intervention1/3 degree of angle of sway (Least Squares Mean)
LY2216684 + Alcohol0.14
Placebo-matching LY2216684 + Alcohol-3.51
LY2216684 + Placebo-matching Alcohol-3.65
Placebo-matching LY2216684 + Placebo-matching Alcohol5.2

[back to top]

Change From Baseline to 10 Hours in Power of Attention Composite Score

Power of attention is a measure of focused attention and information processing speed; based on the summed reaction times from the simple reaction time, choice reaction time, and digit vigilance tasks. Scores are measured by response latencies, and smaller scores indicate better function. Least squares (LS) means were calculated using mixed model analysis of covariance (ANCOVA) adjusting for predose, sequence, period, day, time, treatment, and treatment*time as fixed effects and participant within sequence and treatment as random effect. (NCT01380691)
Timeframe: Baseline, 10 hours

Interventionminutes (Least Squares Mean)
LY2216684 + Alcohol67.82
Placebo-matching LY2216684 + Alcohol52.77
LY2216684 + Placebo-matching Alcohol20.6
Placebo-matching LY2216684 + Placebo-matching Alcohol6.78

[back to top]

Change From Baseline to 10 Hours in Self-Rated Alertness

Assessed via the Bond and Lader Visual Analogue Scale (VAS), which utilizes a 16-point scale of 0 to 100 with 0 representing the worst rating and 100 representing the best rating. LS means were calculated using mixed model ANCOVA adjusting for predose, sequence, period, day, time, treatment, and treatment*time as fixed effects and participant within sequence and treatment as random effect. (NCT01380691)
Timeframe: Baseline, 10 hours

Interventionunits on a scale (Least Squares Mean)
LY2216684 + Alcohol3.85
Placebo-matching LY2216684 + Alcohol-2.37
LY2216684 + Placebo-matching Alcohol11.88
Placebo-matching LY2216684 + Placebo-matching Alcohol3.02

[back to top]

Pharmacokinetics: Area Under the Concentration Time Curve From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Alcohol

(NCT01380691)
Timeframe: Predose through 12 hours postdose

Interventionmillimoles*hours/liters (mmol*h/L) (Geometric Mean)
LY2216684 + Alcohol29.7
Placebo-matching LY2216684 + Alcohol34.5

[back to top]

Pharmacokinetics: Area Under the Concentration Time Curve Over a Dosing Interval (AUCt) of LY2216684

(NCT01380691)
Timeframe: Predose through 24 hours postdose

Interventionnanograms*hours/milliliters (ng*h/mL) (Geometric Mean)
LY2216684 + Alcohol717
LY2216684 + Placebo-matching Alcohol678

[back to top]

Pharmacokinetics: Observed Cmax of Alcohol

(NCT01380691)
Timeframe: Predose through 24 hours postdose

Interventionmillimoles/liters (mmol/L) (Geometric Mean)
LY2216684 + Alcohol11.4
Placebo-matching LY2216684 + Alcohol13.8

[back to top]

Pharmacokinetics: Observed Maximum Plasma Concentration (Cmax) of LY2216684

(NCT01380691)
Timeframe: Predose through 24 hours postdose

Interventionnanograms/milliliters (ng/mL) (Geometric Mean)
LY2216684 + Alcohol60.2
LY2216684 + Placebo-matching Alcohol58.0

[back to top]

Pharmacokinetics: Observed Time to Maximum Plasma Concentration (Tmax) of LY2216684

(NCT01380691)
Timeframe: Predose through 24 hours postdose

Interventionhours (Median)
LY2216684 + Alcohol4.00
LY2216684 + Placebo-matching Alcohol2.94

[back to top]

Pharmacokinetics: Observed Tmax of Alcohol

(NCT01380691)
Timeframe: Predose through 24 hours postdose

Interventionhours (Median)
LY2216684 + Alcohol0.92
Placebo-matching LY2216684 + Alcohol0.92

[back to top]

Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Episodic Memory

"Episodic memory is based on how accurate the participant responds using the measures from immediate word recall (range 0-15), delayed word recall (range 0-15), word recognition (range 0-15), and picture recognition (range 0-20) tasks. The sum of four the accuracy scores, are summed, and averaged to provide a composite score (range 0-37.5). This composite score reflects the ability to store, hold, and retrieve information of an episodic nature (such as an event, a name, an object, a scene, or an appointment). A high score reflects someone able to recall memory for a prolonged period. A negative change from baseline reflects impairment compared to baseline.~LS mean was calculated using mixed model ANCOVA adjusting for predose, sequence, period, day, time, treatment, and treatment*time as fixed effects and participant within sequence and treatment as random effect." (NCT01380691)
Timeframe: Baseline, 1, 2, 3, 4.5, 6, 8, and 10 hours

,,,
Interventionunits on a scale (Geometric Mean)
Hour 1Hour 2Hour 3Hour 4.5Hour 6Hour 8Hour 10
LY2216684 + Alcohol-29.13-96.35-76.72-65.06-39.56-42.28-46.78
LY2216684 + Placebo-matching Alcohol-24.81-44.3-34.92-50.78-41.34-46.09-41.95
Placebo-matching LY2216684 + Alcohol-30.56-97.54-74.27-52.23-49.7-43.65-34.33
Placebo-matching LY2216684 + Placebo-matching Alcohol-19.29-41.64-30.58-34.29-38.86-35.95-39.04

[back to top]

Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Self-Ratings of Calmness and Contentment

Assessed via the Bond and Lader Visual Analogue Scale (VAS), which utilizes a 16-point scale of 0 to 100 with 0 representing the worst rating and 100 representing the best rating. LS means were calculated using mixed model ANCOVA adjusting for predose, sequence, period, day, time, treatment, and treatment*time as fixed effects and participant within sequence and treatment as random effect. (NCT01380691)
Timeframe: Baseline, 1, 2, 3, 4.5, 6, 8, and 10 hours

,,,
Interventionunits on a scale (Least Squares Mean)
Self-rated Alertness, Hour 1Self-rated Alertness, Hour 2Self-rated Alertness, Hour 3Self-rated Alertness, Hour 4.5Self-rated Alertness, Hour 6Self-rated Alertness, Hour 8Self-rated Alertness, Hour 10Self-rated Contentment, Hour 1Self-rated Contentment, Hour 2Self-rated Contentment, Hour 3Self-rated Contentment, Hour 4.5Self-rated Contentment, Hour 6Self-rated Contentment, Hour 8Self-rated Contentment, Hour 10
LY2216684 + Alcohol2.9817.0923.6727.1923.6612.693.853.283.728.4116.9818.149.972.47
LY2216684 + Placebo-matching Alcohol3.640.769.0416.2615.1312.3811.882.771.645.6911.3910.689.6810.16
Placebo-matching LY2216684 + Alcohol4.5714.0826.2520.7417.253.63-2.370.951.57.128.510.850.980.44
Placebo-matching LY2216684 + Placebo-matching Alcohol6.063.641.229.827.553.033.024.342.791.325.034.572.73.72

[back to top]

Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Speed of Retrieval of Information From Memory

"Speed of retrieval is a measure of complex information processing speed, summing reaction times from the two working memory (numeric and spatial) tasks and the two episodic recognition (word recognition and picture recognition) tasks. This composite score reflects the time it takes to decide correctly whether an item is held in working memory or episodic secondary memory.Scores are measured by response latencies, and smaller scores indicate better function. A negative change from baseline reflects impairment compared to baseline.~LS means calculated using mixed model ANCOVA adjusting for predose, sequence, period, day, time, treatment, and treatment*time as fixed effects and participant within sequence and treatment as random effect." (NCT01380691)
Timeframe: Baseline, 1, 2, 3, 4.5, 6, 8, and 10 hours

,,,
Interventionmillisecond (msec) (Least Squares Mean)
Hour 1Hour 2Hour 3Hour 4.5Hour 6Hour 8Hour 10
LY2216684 + Alcohol-38.46104.4843.6930.12-116.69-116.72-74.78
LY2216684 + Placebo-matching Alcohol42.5159.6551.53-121.55-90.4655.62-108.12
Placebo-matching LY2216684 + Alcohol36.22316.09283.6361.9346.44-48.13-136.62
Placebo-matching LY2216684 + Placebo-matching Alcohol138.87197.3724.55169.34-114.87-120.29-129.8

[back to top]

Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Working Memory

"Working memory is a sum of accuracy measures from the numeric and spatial working memory tasks known as the sensitivity index (SI). Working Memory SI is based on how fast the participant responds correctly and how many are correct responses. SI ranging from zero (chance performance) to one (perfect accuracy). A high score reflects someone able to hold in memory for a prolonged period. A negative change from baseline reflects impairment compared to baseline.~A series of 5 digits were presented on a computer screen, every second, for the participant to hold in memory. Followed by 30 probe digits, the participant had to decide whether it appeared in the original series by responding with 'Yes' or 'No'. This was repeated 2 times using different series and probes.~LS mean was calculated using mixed model ANCOVA adjusting for predose, sequence, period, day, time, treatment, and treatment*time as fixed effects and participant within sequence and treatment as random effect." (NCT01380691)
Timeframe: Baseline, 1, 2, 3, 4.5, 6, 8, and 10 hours

,,,
InterventionUnits on a scale (Least Squares Mean)
Hour 1Hour 2Hour 3Hour 4.5Hour 6Hour 8Hour 10
LY2216684 + Alcohol-0.12-0.27-0.2-0.15-0.1-0.03-0.21
LY2216684 + Placebo-matching Alcohol-0.1-0.13-0.06-0.2-0.06-0.08-0.16
Placebo-matching LY2216684 + Alcohol-0.12-0.29-0.18-0.11-0.09-0.05-0.09
Placebo-matching LY2216684 + Placebo-matching Alcohol-0.02-0.12-0.04-0.2-0.07-0.13-0.06

[back to top]